---
title: "Parameters and Calculations Reference"
subtitle: "Comprehensive Documentation of Economic Model Variables"
format:
  html:
    toc: true
    toc-depth: 3
    number-sections: true
    code-fold: true
---

# Overview

This appendix provides comprehensive documentation of all parameters and calculations used in the economic analysis of the 1% Treaty and Decentralized FDA.

**Total parameters**: 525

- External sources (peer-reviewed): 164
- Calculated values: 313
- Core definitions: 48

# External Data Sources {#sec-external}

Parameters sourced from peer-reviewed publications, institutional databases, and authoritative reports.

::: {.callout-tip icon=false collapse=false}
## Accidental/Unintentional Injury Death Rate {#sec-accidents_death_rate}

**Value**: 62.3

Accidental/unintentional injury death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Alzheimer's Disease Death Rate {#sec-alzheimers_death_rate}

**Value**: 27.7

Alzheimer's disease death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Life Extension from Antibiotics {#sec-antibiotics_life_extension_years}

**Value**: 10

Life extension from antibiotics (conservative mid-range from 5-23 years)

**Source**: [life-expectancy-gains-medical-advances](https://warondisease.org/knowledge/references.html#life-expectancy-gains-medical-advances)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Annual Stock Market Return {#sec-average_market_return_pct}

**Value**: 10%

Average annual stock market return (10%)

**Source**: [warren-buffett-career-average-return-20-pct](https://warondisease.org/knowledge/references.html#warren-buffett-career-average-return-20-pct)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average US Hourly Wage {#sec-average_us_hourly_wage}

**Value**: $30

Average US hourly wage

**Source**: [average-us-hourly-wage](https://warondisease.org/knowledge/references.html#average-us-hourly-wage)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Baseline Annual Lives Saved by Pharmaceuticals {#sec-baseline_lives_saved_annual}

**Value**: 12

Baseline annual lives saved by pharmaceuticals (conservative aggregate)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Biometric KYC Verification Cost at Medium Volume (High Estimate) {#sec-biometric_verification_cost_per_user_high_usd}

**Value**: $0

Biometric KYC verification cost at medium volume

**Source**: [kyc-biometric-verification-costs-2024](https://warondisease.org/knowledge/references.html#kyc-biometric-verification-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Biometric KYC Verification Cost at High Volume (Low Estimate) {#sec-biometric_verification_cost_per_user_low_usd}

**Value**: $0

Biometric KYC verification cost at high volume (300M+ scale)

**Source**: [kyc-biometric-verification-costs-2024](https://warondisease.org/knowledge/references.html#kyc-biometric-verification-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Average Reading Speed {#sec-book_reading_speed_wpm}

**Value**: 200

Average reading speed (conservative for non-fiction)

**Source**: [average-reading-speed](https://warondisease.org/knowledge/references.html#average-reading-speed)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cancer Death Rate {#sec-cancer_death_rate}

**Value**: 147

Cancer death rate (all cancers)

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cardiovascular Disease Death Rate {#sec-cardiovascular_death_rate}

**Value**: 201

Cardiovascular disease death rate (heart disease + stroke)

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Annual Value of Unpaid Caregiving in US {#sec-caregiver_annual_value_total}

**Value**: $600B

Total annual value of unpaid caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Number of Unpaid Caregivers in US {#sec-caregiver_count_us}

**Value**: 38M

Number of unpaid caregivers in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Monthly Hours of Unpaid Family Caregiving in US {#sec-caregiver_hours_per_month}

**Value**: 20

Average monthly hours of unpaid family caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Weekly Hours of Unpaid Caregiving {#sec-caregiver_hours_per_week_avg}

**Value**: 25.5

Average weekly hours of unpaid caregiving (25-26 hours/week)

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## AARP Valuation of Caregiving per Hour {#sec-caregiver_value_per_hour}

**Value**: $17

AARP valuation of caregiving per hour

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Estimated Replacement Cost per Hour of Caregiving {#sec-caregiver_value_per_hour_simple}

**Value**: $25

Estimated replacement cost per hour of caregiving

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Estimated Annual Global Economic Benefit from Childhood Vaccination Programs {#sec-childhood_vaccination_annual_benefit}

**Value**: $15B

Estimated annual global economic benefit from childhood vaccination programs (measles, polio, etc.)

**Source**: [childhood-vaccination-economic-benefits](https://warondisease.org/knowledge/references.html#childhood-vaccination-economic-benefits)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment from Childhood Vaccination Programs {#sec-childhood_vaccination_roi}

**Value**: 13

Return on investment from childhood vaccination programs

**Source**: [childhood-vaccination-roi](https://warondisease.org/knowledge/references.html#childhood-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Disability Weight for Untreated Chronic Conditions {#sec-chronic_disease_disability_weight}

**Value**: 0.35

Disability weight for untreated chronic conditions (WHO Global Burden of Disease)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Current Active Trials at Any Given Time {#sec-current_active_trials}

**Value**: 10,000

Current active trials at any given time (3-5 year duration)

**Source**: [clinicaltrials-gov-enrollment-data-2025](https://warondisease.org/knowledge/references.html#clinicaltrials-gov-enrollment-data-2025)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Clinical Trial Participation Rate {#sec-current_clinical_trial_participation_rate}

**Value**: 0.06%

Current clinical trial participation rate (0.06% of population)

**Source**: [clinical-trial-patient-participation-rate](https://warondisease.org/knowledge/references.html#clinical-trial-patient-participation-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Population with Chronic Diseases {#sec-current_disease_patients_global}

**Value**: 2.40B

Global population with chronic diseases

**Source**: [disease-prevalence-2-billion](https://warondisease.org/knowledge/references.html#disease-prevalence-2-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Annual New Drug Approvals Globally {#sec-current_drug_approvals_per_year}

**Value**: 50

Average annual new drug approvals globally

**Source**: [global-new-drug-approvals-50-annually](https://warondisease.org/knowledge/references.html#global-new-drug-approvals-50-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Patient Eligibility Rate for Clinical Trials {#sec-current_patient_eligibility_rate}

**Value**: 0.2%

Current patient eligibility rate for clinical trials (0.2%)

**Source**: [clinical-trial-eligibility-rate](https://warondisease.org/knowledge/references.html#clinical-trial-eligibility-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Global Clinical Trials per Year {#sec-current_trials_per_year}

**Value**: 3,300

Current global clinical trials per year

**Source**: [global-clinical-trials-market-2024](https://warondisease.org/knowledge/references.html#global-clinical-trials-market-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trial Abandonment Rate {#sec-current_trial_abandonment_rate}

**Value**: 40%

Current trial abandonment rate (40% never complete)

**Source**: [clinical-trial-abandonment-rate](https://warondisease.org/knowledge/references.html#clinical-trial-abandonment-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trial Completion Rate {#sec-current_trial_completion_rate}

**Value**: 60%

Current trial completion rate (60%)

**Source**: [clinical-trial-completion-rate](https://warondisease.org/knowledge/references.html#clinical-trial-completion-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Trial Slots Available for 2.4b Sick People {#sec-current_trial_slots_available}

**Value**: 5.00M

Total trial slots available for 2.4B sick people

**Source**: [global-trial-participant-capacity](https://warondisease.org/knowledge/references.html#global-trial-participant-capacity)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Defense Industry Lobbying Spending {#sec-defense_lobbying_annual}

**Value**: $127M

Annual defense industry lobbying spending

**Source**: [lobbying-spend-defense](https://warondisease.org/knowledge/references.html#lobbying-spend-defense)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Diabetes Death Rate {#sec-diabetes_death_rate}

**Value**: 22.4

Diabetes death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Monthly Cost of Diabetes Treatment per Patient {#sec-diabetes_treatment_monthly_cost}

**Value**: $500

Average monthly cost of diabetes treatment per patient

**Source**: [disease-cost-diabetes-1500b](https://warondisease.org/knowledge/references.html#disease-cost-diabetes-1500b)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier for Education Investment {#sec-economic_multiplier_education_investment}

**Value**: 2.1

Economic multiplier for education investment (2.1x ROI)

**Source**: [education-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#education-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier for Healthcare Investment {#sec-economic_multiplier_healthcare_investment}

**Value**: 4.3

Economic multiplier for healthcare investment (4.3x ROI)

**Source**: [healthcare-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#healthcare-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier for Infrastructure Investment {#sec-economic_multiplier_infrastructure_investment}

**Value**: 1.6

Economic multiplier for infrastructure investment (1.6x ROI)

**Source**: [infrastructure-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#infrastructure-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier for Military Spending {#sec-economic_multiplier_military_spending}

**Value**: 0.6

Economic multiplier for military spending (0.6x ROI)

**Source**: [military-spending-economic-multiplier](https://warondisease.org/knowledge/references.html#military-spending-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Regulatory Delay for Efficacy Testing Post-Safety Verification {#sec-efficacy_lag_years}

**Value**: 8.2

Regulatory delay for efficacy testing (Phase II/III) post-safety verification

**Source**: [bio-clinical-development-2021](https://warondisease.org/knowledge/references.html#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Average Cost per Life Saved Across Top Charities {#sec-givewell_cost_per_life_avg}

**Value**: $4.50K

GiveWell average cost per life saved across top charities

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Cost per Life Saved (Maximum) {#sec-givewell_cost_per_life_max}

**Value**: $5.50K

GiveWell cost per life saved (Against Malaria Foundation)

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Cost per Life Saved (Minimum) {#sec-givewell_cost_per_life_min}

**Value**: $3.50K

GiveWell cost per life saved (Helen Keller International)

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Deaths from Active Combat Worldwide {#sec-global_annual_conflict_deaths_active_combat}

**Value**: 234K

Annual deaths from active combat worldwide

**Source**: [acled-active-combat-deaths](https://warondisease.org/knowledge/references.html#acled-active-combat-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Deaths from State Violence {#sec-global_annual_conflict_deaths_state_violence}

**Value**: 2,700

Annual deaths from state violence

**Source**: [ucdp-state-violence-deaths](https://warondisease.org/knowledge/references.html#ucdp-state-violence-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Deaths from Terror Attacks Globally {#sec-global_annual_conflict_deaths_terror_attacks}

**Value**: 8,300

Annual deaths from terror attacks globally

**Source**: [gtd-terror-attack-deaths](https://warondisease.org/knowledge/references.html#gtd-terror-attack-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Environmental Damage and Restoration Costs from Conflict {#sec-global_annual_environmental_damage_conflict}

**Value**: $100B

Annual environmental damage and restoration costs from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Communications from Conflict {#sec-global_annual_infrastructure_damage_communications_conflict}

**Value**: $298B

Annual infrastructure damage to communications from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Education Facilities from Conflict {#sec-global_annual_infrastructure_damage_education_conflict}

**Value**: $234B

Annual infrastructure damage to education facilities from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Energy Systems from Conflict {#sec-global_annual_infrastructure_damage_energy_conflict}

**Value**: $422B

Annual infrastructure damage to energy systems from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Healthcare Facilities from Conflict {#sec-global_annual_infrastructure_damage_healthcare_conflict}

**Value**: $166B

Annual infrastructure damage to healthcare facilities from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Transportation from Conflict {#sec-global_annual_infrastructure_damage_transportation_conflict}

**Value**: $487B

Annual infrastructure damage to transportation from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Infrastructure Damage to Water Systems from Conflict {#sec-global_annual_infrastructure_damage_water_conflict}

**Value**: $268B

Annual infrastructure damage to water systems from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Lives Saved by Medical Research Globally {#sec-global_annual_lives_saved_by_med_research}

**Value**: 4.20M

Annual lives saved by medical research globally

**Source**: [medical-research-lives-saved-annually](https://warondisease.org/knowledge/references.html#medical-research-lives-saved-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Lost Economic Growth from Military Spending Opportunity Cost {#sec-global_annual_lost_economic_growth_military_spending}

**Value**: $2.72T

Annual lost economic growth from military spending opportunity cost

**Source**: [disparity-ratio-weapons-vs-cures](https://warondisease.org/knowledge/references.html#disparity-ratio-weapons-vs-cures)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Lost Productivity from Conflict Casualties {#sec-global_annual_lost_human_capital_conflict}

**Value**: $300B

Annual lost productivity from conflict casualties

**Source**: [lost-human-capital-war-cost](https://warondisease.org/knowledge/references.html#lost-human-capital-war-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending on Infrastructure in 2024 {#sec-global_annual_military_spending_infrastructure_2024}

**Value**: $520B

Global military spending on infrastructure in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending on Intelligence in 2024 {#sec-global_annual_military_spending_intelligence_2024}

**Value**: $282B

Global military spending on intelligence in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending on Operations and Maintenance in 2024 {#sec-global_annual_military_spending_ops_maintenance_2024}

**Value**: $580B

Global military spending on operations and maintenance in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending on Personnel in 2024 {#sec-global_annual_military_spending_personnel_2024}

**Value**: $682B

Global military spending on personnel in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending on Procurement in 2024 {#sec-global_annual_military_spending_procurement_2024}

**Value**: $654B

Global military spending on procurement in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual PTSD and Mental Health Costs from Conflict {#sec-global_annual_psychological_impact_costs_conflict}

**Value**: $232B

Annual PTSD and mental health costs from conflict

**Source**: [psychological-impact-war-cost](https://warondisease.org/knowledge/references.html#psychological-impact-war-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Refugee Support Costs {#sec-global_annual_refugee_support_costs}

**Value**: $150B

Annual refugee support costs (108.4M refugees Ã— $1,384/year)

**Source**: [unhcr-refugee-support-cost](https://warondisease.org/knowledge/references.html#unhcr-refugee-support-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Trade Disruption Costs from Currency Instability {#sec-global_annual_trade_disruption_currency_conflict}

**Value**: $57.4B

Annual trade disruption costs from currency instability

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Trade Disruption Costs from Energy Price Volatility {#sec-global_annual_trade_disruption_energy_price_conflict}

**Value**: $125B

Annual trade disruption costs from energy price volatility

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Trade Disruption Costs from Shipping Disruptions {#sec-global_annual_trade_disruption_shipping_conflict}

**Value**: $247B

Annual trade disruption costs from shipping disruptions

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Trade Disruption Costs from Supply Chain Disruptions {#sec-global_annual_trade_disruption_supply_chain_conflict}

**Value**: $187B

Annual trade disruption costs from supply chain disruptions

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Veteran Healthcare Costs {#sec-global_annual_veteran_healthcare_costs}

**Value**: $200B

Annual veteran healthcare costs (20-year projected)

**Source**: [veteran-healthcare-cost-projections](https://warondisease.org/knowledge/references.html#veteran-healthcare-cost-projections)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Global Spending on Clinical Trials {#sec-global_clinical_trials_spending_annual}

**Value**: $83B

Annual global spending on clinical trials

**Source**: [global-clinical-trials-market-2024](https://warondisease.org/knowledge/references.html#global-clinical-trials-market-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Clinical Trial Market Size {#sec-global_clinical_trial_market_annual}

**Value**: $100B

Global clinical trial market size

**Source**: [clinical-trial-market-size](https://warondisease.org/knowledge/references.html#clinical-trial-market-size)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Annual Cost per Refugee Globally {#sec-global_cost_per_refugee_per_year_average}

**Value**: $1.38K

Average annual cost per refugee globally

**Source**: [unhcr-refugee-support-cost](https://warondisease.org/knowledge/references.html#unhcr-refugee-support-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Daily Deaths from Curable Diseases Globally {#sec-global_daily_deaths_curable_diseases}

**Value**: 150K

Daily deaths from curable diseases globally

**Source**: [deaths-from-treatable-diseases-15m](https://warondisease.org/knowledge/references.html#deaths-from-treatable-diseases-15m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Direct Medical Costs of Disease {#sec-global_disease_direct_medical_cost_annual}

**Value**: $9.90T

Direct medical costs of disease globally (treatment, hospitalization, medication)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Economic Value of Human Life Lost to Disease {#sec-global_disease_human_life_value_loss_annual}

**Value**: $94.2T

Economic value of human life lost to disease annually (mortality valuation)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Productivity Loss from Disease {#sec-global_disease_productivity_loss_annual}

**Value**: $5.00T

Annual productivity loss from disease globally (absenteeism, reduced output)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Cost to Achieve Universal Education {#sec-global_education_for_all_cost}

**Value**: $30B

Global cost to achieve universal education

**Source**: [unesco-education-for-all-cost](https://warondisease.org/knowledge/references.html#unesco-education-for-all-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Forcibly Displaced People in 2023 {#sec-global_forcibly_displaced_people_2023}

**Value**: 108M

Global forcibly displaced people in 2023

**Source**: [unhcr-forcibly-displaced-2023](https://warondisease.org/knowledge/references.html#unhcr-forcibly-displaced-2023)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global GDP in 2023 for Comparison {#sec-global_gdp_2023}

**Value**: $89.5T

Global GDP in 2023 for comparison

**Source**: [global-gdp](https://warondisease.org/knowledge/references.html#global-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global GDP in 2024 {#sec-global_gdp_2024}

**Value**: $111T

Global GDP in 2024

**Source**: [global-gdp](https://warondisease.org/knowledge/references.html#global-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Healthcare Spending in 2024 {#sec-global_healthcare_spending_annual_2024}

**Value**: $9.80T

Global healthcare spending in 2024

**Source**: [global-health-spending-gdp](https://warondisease.org/knowledge/references.html#global-health-spending-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Life Expectancy (2024) {#sec-global_life_expectancy_2024}

**Value**: 79

Global life expectancy (2024)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Global Government Medical Research Spending {#sec-global_med_research_spending}

**Value**: $67.5B

Global government medical research spending

**Source**: [global-gov-med-research-spending](https://warondisease.org/knowledge/references.html#global-gov-med-research-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending in 2024 {#sec-global_military_spending_annual_2024}

**Value**: $2.72T

Global military spending in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Increase in Global Nuclear Weapons Budget {#sec-global_nuclear_weapons_annual_budget_increase}

**Value**: $42B

Annual increase in global nuclear weapons budget

**Source**: [global-nuclear-weapon-maintenance-100b](https://warondisease.org/knowledge/references.html#global-nuclear-weapon-maintenance-100b)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Population in 2024 {#sec-global_population_2024}

**Value**: 8.00B

Global population in 2024

**Source**: [global-population-8-billion](https://warondisease.org/knowledge/references.html#global-population-8-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Critical Mass Threshold for Social Change {#sec-global_population_activism_threshold_pct}

**Value**: 3.5%

Critical mass threshold for social change (3.5% rule)

**Source**: [3-5-rule](https://warondisease.org/knowledge/references.html#3-5-rule)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Cost to Eradicate Global Poverty {#sec-global_poverty_eradication_cost_total}

**Value**: $1.00T

Total cost to eradicate global poverty

**Source**: [world-bank-poverty-eradication-cost](https://warondisease.org/knowledge/references.html#world-bank-poverty-eradication-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Global Spending on Symptomatic Disease Treatment {#sec-global_symptomatic_disease_treatment_annual}

**Value**: $8.20T

Annual global spending on symptomatic disease treatment

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Kidney Disease Death Rate {#sec-kidney_disease_death_rate}

**Value**: 13.1

Kidney disease death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Liver Disease Death Rate {#sec-liver_disease_death_rate}

**Value**: 13

Liver disease death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment for Defense Lobbying {#sec-lobbying_roi_defense}

**Value**: 1,813

Return on investment for defense lobbying ($1,813 returned per $1 spent)

**Source**: [military-lobbying-returns](https://warondisease.org/knowledge/references.html#military-lobbying-returns)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Maximum Annual Lobbyist Salary Range {#sec-lobbyist_salary_max}

**Value**: $2.00M

Maximum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](https://warondisease.org/knowledge/references.html#lobbyist-statistics-dc)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Minimum Annual Lobbyist Salary Range {#sec-lobbyist_salary_min_k}

**Value**: $500K

Minimum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](https://warondisease.org/knowledge/references.html#lobbyist-statistics-dc)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical Annual Lobbyist Salary for Comparison {#sec-lobbyist_salary_typical_k}

**Value**: $500K

Typical annual lobbyist salary for comparison

**Source**: [lobbyist-statistics-dc](https://warondisease.org/knowledge/references.html#lobbyist-statistics-dc)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment from Measles Vaccination Programs {#sec-measles_vaccination_roi}

**Value**: 14

Return on investment from measles (MMR) vaccination programs

**Source**: [measles-vaccination-roi](https://warondisease.org/knowledge/references.html#measles-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Hourly Cost of Medical Facility Room {#sec-medical_facility_hourly_room_cost}

**Value**: $500

Average hourly cost of medical facility room

**Source**: [hospital-room-costs](https://warondisease.org/knowledge/references.html#hospital-room-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Mental Health Research Grants Total {#sec-mental_health_grants_annual}

**Value**: $500M

Annual mental health research grants total

**Source**: [global-mental-health-research-spending-1-5b](https://warondisease.org/knowledge/references.html#global-mental-health-research-spending-1-5b)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Productivity Loss per Capita from Mental Health Issues {#sec-mental_health_productivity_loss_per_capita}

**Value**: $2.00K

Annual productivity loss per capita from mental health issues (beyond treatment costs)

**Source**: [mental-health-burden](https://warondisease.org/knowledge/references.html#mental-health-burden)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Other Causes Death Rate {#sec-other_death_rate}

**Value**: 250

Other causes death rate per 100,000 population

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Cost per Verified Petition Signature in 2024 US Campaigns {#sec-petition_signature_cost_per_verified_2024}

**Value**: $15

Average cost per verified petition signature in 2024 US campaigns

**Source**: [ballot-measure-signature-costs-2024](https://warondisease.org/knowledge/references.html#ballot-measure-signature-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Pharma Drug Development Cost (Current System) {#sec-pharma_drug_development_cost_current}

**Value**: $2.60B

Average cost to develop one drug in current system

**Source**: [drug-development-cost](https://warondisease.org/knowledge/references.html#drug-development-cost)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Pharma Average Drug Revenue (Current System) {#sec-pharma_drug_revenue_average_current}

**Value**: $6.70B

Median lifetime revenue per successful drug (study of 361 FDA-approved drugs 1995-2014, median follow-up 13.2 years)

**Source**: [pharma-drug-revenue-average](https://warondisease.org/knowledge/references.html#pharma-drug-revenue-average)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Pharma ROI (Current System) {#sec-pharma_roi_current_system_pct}

**Value**: 1.2%

ROI for pharma R&D (2022 historic low from Deloitte study of top 20 pharma companies, down from 6.8% in 2021, recovered to 5.9% in 2024)

**Source**: [pharma-roi-current](https://warondisease.org/knowledge/references.html#pharma-roi-current)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Pharma Drug Success Rate (Current System) {#sec-pharma_success_rate_current_pct}

**Value**: 10%

Percentage of drugs that reach market in current system

**Source**: [drug-trial-success-rate-12-pct](https://warondisease.org/knowledge/references.html#drug-trial-success-rate-12-pct)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Phase I Safety Trial Duration {#sec-phase_1_safety_duration_years}

**Value**: 2.3

Phase I safety trial duration

**Source**: [bio-clinical-development-2021](https://warondisease.org/knowledge/references.html#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 3 Trial Total Cost (Maximum) {#sec-phase_3_trial_cost_max}

**Value**: $282M

Phase 3 trial total cost (maximum)

**Source**: [phase-3-cost-per-trial-range](https://warondisease.org/knowledge/references.html#phase-3-cost-per-trial-range)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 3 Trial Total Cost (Minimum) {#sec-phase_3_trial_cost_min}

**Value**: $20M

Phase 3 trial total cost (minimum)

**Source**: [phase-3-cost-per-trial-range](https://warondisease.org/knowledge/references.html#phase-3-cost-per-trial-range)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs {#sec-polio_vaccination_roi}

**Value**: 39

Return on investment from sustaining polio vaccination assets and integrating into expanded immunization programs

**Source**: [polio-vaccination-roi](https://warondisease.org/knowledge/references.html#polio-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Conservative Estimate of Political Success Probability {#sec-political_success_probability_conservative}

**Value**: 0.1

Conservative estimate of political success probability (10%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Moderate Estimate of Political Success Probability {#sec-political_success_probability_moderate}

**Value**: 0.25

Moderate estimate of political success probability (25%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Optimistic Estimate of Political Success Probability {#sec-political_success_probability_optimistic}

**Value**: 0.5

Optimistic estimate of political success probability (50%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Percentage Military Spending Cut After WW2 {#sec-post_ww2_military_cut_pct}

**Value**: 30%

Percentage military spending cut after WW2 (historical precedent)

**Source**: [us-post-wwii-military-spending-cut](https://warondisease.org/knowledge/references.html#us-post-wwii-military-spending-cut)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Productivity Loss per Affected Employee {#sec-productivity_loss_per_affected_employee}

**Value**: $4.80K

Annual productivity loss per affected employee (IBI 2024)

**Source**: [chronic-illness-workforce-productivity-loss](https://warondisease.org/knowledge/references.html#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Number of Rare Diseases Globally {#sec-rare_diseases_count_global}

**Value**: 7,000

Total number of rare diseases globally

**Source**: [95-pct-diseases-no-treatment](https://warondisease.org/knowledge/references.html#95-pct-diseases-no-treatment)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical Patient Count for Rare Diseases {#sec-rare_disease_typical_patient_count}

**Value**: 500

Typical patient count for rare diseases

**Source**: [rare-disease-prevalence-400m](https://warondisease.org/knowledge/references.html#rare-disease-prevalence-400m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Recovery Trial Cost per Patient {#sec-recovery_trial_cost_per_patient}

**Value**: $500

RECOVERY trial cost per patient

**Source**: [recovery-cost-500](https://warondisease.org/knowledge/references.html#recovery-cost-500)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment for Early Adopters {#sec-referral_payment_early_adopters_usd}

**Value**: $0

Referral payment for early adopters (first 10M, motivated believers)

**Source**: [paypal-dropbox-referral-case-studies](https://warondisease.org/knowledge/references.html#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment for Laggards {#sec-referral_payment_laggards_usd}

**Value**: $2

Referral payment for laggards (200-280M, resistant)

**Source**: [paypal-dropbox-referral-case-studies](https://warondisease.org/knowledge/references.html#paypal-dropbox-referral-case-studies)

*? Low confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment for Late Majority {#sec-referral_payment_late_majority_usd}

**Value**: $1

Referral payment for late majority (100-200M, skeptics)

**Source**: [paypal-dropbox-referral-case-studies](https://warondisease.org/knowledge/references.html#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment for Mainstream Adopters {#sec-referral_payment_mainstream_usd}

**Value**: $0

Referral payment for mainstream adopters (10-100M, pragmatists)

**Source**: [paypal-dropbox-referral-case-studies](https://warondisease.org/knowledge/references.html#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Average Annual Lost Earning Potential per Refugee {#sec-refugee_lost_earning_potential_per_capita_annual}

**Value**: $23.4K

Average annual lost earning potential per refugee

**Source**: [refugee-lost-earning-potential](https://warondisease.org/knowledge/references.html#refugee-lost-earning-potential)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Mean Age of Preventable Death from Regulatory Delay {#sec-regulatory_delay_mean_age_of_death}

**Value**: 62

Mean age of preventable death from regulatory delay

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Pre-Death Suffering Period for Regulatory Delay Deaths {#sec-regulatory_delay_suffering_period_years}

**Value**: 6

Pre-death suffering period for regulatory delay deaths (average years lived with untreated condition)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Chronic Respiratory Disease Death Rate {#sec-respiratory_death_rate}

**Value**: 33.4

Chronic respiratory disease death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment from Smallpox Eradication Campaign {#sec-smallpox_eradication_roi}

**Value**: 280

Return on investment from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](https://warondisease.org/knowledge/references.html#smallpox-eradication-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Maximum Monthly Cost for Software Tools/Services {#sec-software_tool_monthly_cost_max}

**Value**: $2.00K

Maximum monthly cost for software tools/services

**Source**: [software-pricing-market-rates](https://warondisease.org/knowledge/references.html#software-pricing-market-rates)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Minimum Monthly Cost for Software Tools/Services {#sec-software_tool_monthly_cost_min}

**Value**: $500

Minimum monthly cost for software tools/services

**Source**: [software-pricing-market-rates](https://warondisease.org/knowledge/references.html#software-pricing-market-rates)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Standard Economic Value per QALY {#sec-standard_economic_qaly_value_usd}

**Value**: $150K

Standard economic value per QALY

**Source**: [qaly-value](https://warondisease.org/knowledge/references.html#qaly-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Standard QALYs per Life Saved {#sec-standard_qalys_per_life_saved}

**Value**: 35

Standard QALYs per life saved (WHO life tables)

**Source**: [qaly-value](https://warondisease.org/knowledge/references.html#qaly-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Annual Cost of Sugar Subsidies per Person {#sec-sugar_subsidy_cost_per_person_annual}

**Value**: $10

Annual cost of sugar subsidies per person

**Source**: [sugar-subsidies-cost](https://warondisease.org/knowledge/references.html#sugar-subsidies-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Switzerland's Defense Spending as Percentage of GDP {#sec-switzerland_defense_spending_pct}

**Value**: 0.7%

Switzerland's defense spending as percentage of GDP (0.7%)

**Source**: [swiss-military-budget-0-7-pct-gdp](https://warondisease.org/knowledge/references.html#swiss-military-budget-0-7-pct-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Switzerland GDP per Capita {#sec-switzerland_gdp_per_capita_k}

**Value**: $93K

Switzerland GDP per capita

**Source**: [swiss-vs-us-gdp-per-capita](https://warondisease.org/knowledge/references.html#swiss-vs-us-gdp-per-capita)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Deaths from 9/11 Terrorist Attacks {#sec-terrorism_deaths_911}

**Value**: 2,996

Deaths from 9/11 terrorist attacks

**Source**: [chance-of-dying-from-terrorism-1-in-30m](https://warondisease.org/knowledge/references.html#chance-of-dying-from-terrorism-1-in-30m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Overall Age-Adjusted Death Rate {#sec-total_death_rate}

**Value**: 722

Overall age-adjusted death rate

**Source**: [leading-causes-of-death-by-age-group](https://warondisease.org/knowledge/references.html#leading-causes-of-death-by-age-group)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Life Expectancy Gain from All Medical Advances 1900-2000 {#sec-total_medical_advances_1900_2000}

**Value**: 35

Total life expectancy gain from all medical advances 1900-2000 (vaccines + hygiene + antibiotics)

**Source**: [life-expectancy-gains-medical-advances](https://warondisease.org/knowledge/references.html#life-expectancy-gains-medical-advances)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical Phase 3 Trial Size {#sec-traditional_large_trial_size}

**Value**: 1,000

Typical Phase 3 trial size

**Source**: [phase-3-participant-numbers](https://warondisease.org/knowledge/references.html#phase-3-participant-numbers)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 2 Cost per Patient (High Estimate) {#sec-traditional_phase2_cost_per_patient_high}

**Value**: $120K

Phase 2 cost per patient (high estimate)

**Source**: [clinical-trial-cost-per-patient](https://warondisease.org/knowledge/references.html#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 2 Cost per Patient (Low Estimate) {#sec-traditional_phase2_cost_per_patient_low}

**Value**: $40K

Phase 2 cost per patient (low estimate)

**Source**: [clinical-trial-cost-per-patient](https://warondisease.org/knowledge/references.html#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient}

**Value**: $80K

Phase 3 cost per patient (median)

**Source**: [phase-3-cost-per-patient-113k](https://warondisease.org/knowledge/references.html#phase-3-cost-per-patient-113k)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Example Phase 3 Trial Cost per Patient {#sec-traditional_phase3_cost_per_patient_example_48k}

**Value**: $48K

Example Phase 3 trial cost per patient ($48K)

**Source**: [clinical-trial-cost-per-patient](https://warondisease.org/knowledge/references.html#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## FDA Cited Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient_fda_example_41k}

**Value**: $41K

FDA cited Phase 3 cost per patient ($41K)

**Source**: [trial-costs-fda-study](https://warondisease.org/knowledge/references.html#trial-costs-fda-study)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical Phase 2 Trial Size {#sec-traditional_small_trial_size}

**Value**: 100

Typical Phase 2 trial size

**Source**: [phase-2-participant-numbers](https://warondisease.org/knowledge/references.html#phase-2-participant-numbers)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional FDA Drug Development Timeline {#sec-treatment_acceleration_years_current}

**Value**: 17

Traditional FDA drug development timeline

**Source**: [fda-approval-timeline-10-years](https://warondisease.org/knowledge/references.html#fda-approval-timeline-10-years)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cost Reduction Factor Demonstrated by Recovery Trial {#sec-trial_cost_reduction_factor}

**Value**: 82

Cost reduction factor demonstrated by RECOVERY trial

**Source**: [recovery-trial-82x-cost-reduction](https://warondisease.org/knowledge/references.html#recovery-trial-82x-cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical CEO Hourly Rate {#sec-typical_ceo_hourly_rate}

**Value**: $10K

Typical CEO hourly rate

**Source**: [ceo-compensation](https://warondisease.org/knowledge/references.html#ceo-compensation)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Alzheimer's Annual Cost {#sec-us_alzheimers_annual_cost}

**Value**: $355B

Annual US cost of Alzheimer's disease (direct and indirect)

**Source**: [disease-cost-alzheimers-1300b](https://warondisease.org/knowledge/references.html#disease-cost-alzheimers-1300b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## Annual US Pharmaceutical Spending {#sec-us_annual_drug_spending}

**Value**: $360B

Annual US pharmaceutical spending

**Source**: [us-drug-spend](https://warondisease.org/knowledge/references.html#us-drug-spend)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Cancer Annual Cost {#sec-us_cancer_annual_cost}

**Value**: $208B

Annual US cost of cancer (direct and indirect)

**Source**: [disease-cost-cancer-1800b](https://warondisease.org/knowledge/references.html#disease-cost-cancer-1800b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## US Annual Chronic Disease Spending {#sec-us_chronic_disease_spending_annual}

**Value**: $4.10T

US annual chronic disease spending

**Source**: [us-chronic-disease-spending](https://warondisease.org/knowledge/references.html#us-chronic-disease-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Defense Budget in 2024 {#sec-us_defense_budget_annual}

**Value**: $877B

US defense budget in 2024

**Source**: [us-military-budget-800b](https://warondisease.org/knowledge/references.html#us-military-budget-800b)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Diabetes Annual Cost {#sec-us_diabetes_annual_cost}

**Value**: $327B

Annual US cost of diabetes (direct and indirect)

**Source**: [disease-cost-diabetes-1500b](https://warondisease.org/knowledge/references.html#disease-cost-diabetes-1500b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## US Department of Transportation Value of Statistical Life {#sec-us_dot_value_of_statistical_life}

**Value**: $13.6M

US Department of Transportation value of statistical life

**Source**: [dot-vsl-13-6m](https://warondisease.org/knowledge/references.html#dot-vsl-13-6m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Drug Prices Compared to Peer Countries Multiplier {#sec-us_drug_price_multiplier_vs_peer_countries}

**Value**: 2.78

US drug prices compared to peer countries multiplier

**Source**: [us-drug-prices-vs-peer-countries](https://warondisease.org/knowledge/references.html#us-drug-prices-vs-peer-countries)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Heart Disease Annual Cost {#sec-us_heart_disease_annual_cost}

**Value**: $363B

Annual US cost of heart disease and stroke (direct and indirect)

**Source**: [disease-cost-heart-disease-2100b](https://warondisease.org/knowledge/references.html#disease-cost-heart-disease-2100b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
## US Median Salary in 2024 {#sec-us_median_salary}

**Value**: $59.4K

US median salary in 2024

**Source**: [us-median-salary-2024](https://warondisease.org/knowledge/references.html#us-median-salary-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Mental Health Costs {#sec-us_mental_health_cost_annual}

**Value**: $350B

US mental health costs (treatment + productivity loss)

**Source**: [mental-health-burden](https://warondisease.org/knowledge/references.html#mental-health-burden)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Military Spending as Percentage of GDP {#sec-us_military_spending_pct_gdp}

**Value**: 3.5%

US military spending as percentage of GDP (2024)

**Source**: [us-military-budget-3-5-pct-gdp](https://warondisease.org/knowledge/references.html#us-military-budget-3-5-pct-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## US Population in 2024 {#sec-us_population_2024}

**Value**: 335M

US population in 2024

**Source**: [us-voter-population](https://warondisease.org/knowledge/references.html#us-voter-population)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Value of Statistical Life {#sec-value_of_statistical_life}

**Value**: $10M

Value of Statistical Life (conservative estimate)

**Source**: [dot-vsl-13-6m](https://warondisease.org/knowledge/references.html#dot-vsl-13-6m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Identity Verification Completion Rate with Good UX {#sec-verification_conversion_rate_good_ux}

**Value**: 85%

Identity verification completion rate with good UX (fintech data)

**Source**: [fintech-identity-verification-conversion-2024](https://warondisease.org/knowledge/references.html#fintech-identity-verification-conversion-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Identity Verification Completion Rate with Poor UX {#sec-verification_conversion_rate_poor_ux}

**Value**: 50%

Identity verification completion rate with poor UX

**Source**: [fintech-identity-verification-conversion-2024](https://warondisease.org/knowledge/references.html#fintech-identity-verification-conversion-2024)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## EPA Value of Statistical Life {#sec-vsl_epa}

**Value**: $9.60M

EPA value of statistical life

**Source**: [epa-vsl-9-6m](https://warondisease.org/knowledge/references.html#epa-vsl-9-6m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Return on Investment from Water Fluoridation Programs {#sec-water_fluoridation_roi}

**Value**: 23

Return on investment from water fluoridation programs

**Source**: [clean-water-sanitation-roi](https://warondisease.org/knowledge/references.html#clean-water-sanitation-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cost-Effectiveness Threshold ($50,000/QALY) {#sec-who_qaly_threshold_cost_effective}

**Value**: $50K

Cost-effectiveness threshold widely used in US health economics ($50,000/QALY, from 1980s dialysis costs)

**Source**: [who-cost-effectiveness-threshold](https://warondisease.org/knowledge/references.html#who-cost-effectiveness-threshold)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Workforce with at Least One Chronic Condition {#sec-workforce_chronic_illness_prevalence}

**Value**: 78.4%

Workforce with at least one chronic condition (78.4%)

**Source**: [chronic-illness-workforce-productivity-loss](https://warondisease.org/knowledge/references.html#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Percentage of Workforce Experiencing Productivity Loss from Chronic Illness {#sec-workforce_with_productivity_loss}

**Value**: 28%

Percentage of workforce experiencing productivity loss from chronic illness (28%)

**Source**: [chronic-illness-workforce-productivity-loss](https://warondisease.org/knowledge/references.html#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## World War Ii War Bond Return Percentage {#sec-ww2_bond_return_pct}

**Value**: 4%

World War II war bond return percentage (4%)

**Source**: [wwii-war-bonds](https://warondisease.org/knowledge/references.html#wwii-war-bonds)

*âœ“ High confidence*

:::

# Calculated Values {#sec-calculated}

Parameters derived from mathematical formulas and economic models.

::: {.callout-note icon=false collapse=false}
## Time to Invest (Minimum) {#sec-action_time_invest_minutes}

**Value**: 10

Time to invest (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Time to Recruit Others (Minimum) {#sec-action_time_recruit_minutes}

**Value**: 15

Time to recruit others (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Action Time in Hours {#sec-action_time_total_hours}

**Value**: 0.45

Total action time in hours

$$
Hours = 27 / 60 = 0.45 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Time for All Three Actions (Minimum) {#sec-action_time_total_minutes}

**Value**: 27

Total time for all three actions

$$
TotalTime = 2 + 10 + 15 = 27 \text{ minutes}
$$

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Time to Vote (Minimum) {#sec-action_time_vote_minutes}

**Value**: 2

Time to vote (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Estimated Bounty Value for Alzheimer's Cure {#sec-alzheimer_cure_bounty_estimate}

**Value**: $10B

Estimated bounty value for Alzheimer's cure

**Methodology**: [Cure Bounty Estimation Model](#cure-bounty-estimates)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from R&D Savings Passed to Consumers {#sec-benefit_drug_price_reduction_annual}

**Value**: $100B

Annual benefit from R&D savings passed to consumers

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#price-reduction](../appendix/dfda-cost-benefit-analysis.qmd#price-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from 7-Year Drug Access Acceleration {#sec-benefit_earlier_drug_access_annual}

**Value**: $300B

Annual benefit from 7-year drug access acceleration

**Methodology**: [../appendix/economic-value-of-accelerated-treatments.qmd](../appendix/economic-value-of-accelerated-treatments.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from 115x Research Capacity Increase {#sec-benefit_medical_research_acceleration_annual}

**Value**: $100B

Annual benefit from 115x research capacity increase

**Methodology**: [../appendix/research-acceleration-model.qmd](../appendix/research-acceleration-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from Mental Health Treatment Gap Reduction {#sec-benefit_mental_health_annual}

**Value**: $75B

Annual benefit from mental health treatment gap reduction

**Methodology**: [../appendix/dfda-qaly-model.qmd#mental-health](../appendix/dfda-qaly-model.qmd#mental-health)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from Economic Viability of Prevention {#sec-benefit_prevention_annual}

**Value**: $100B

Annual benefit from economic viability of prevention

**Methodology**: [../appendix/dfda-qaly-model.qmd#prevention](../appendix/dfda-qaly-model.qmd#prevention)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Benefit from Orphan Drug Viability {#sec-benefit_rare_diseases_annual}

**Value**: $400B

Annual benefit from orphan drug viability

**Methodology**: [../appendix/dfda-qaly-model.qmd#rare-diseases](../appendix/dfda-qaly-model.qmd#rare-diseases)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Time to Read the Entire Book {#sec-book_reading_time_hours}

**Value**: 14.3

Time to read the entire book

$$
ReadTime = \frac{171,121 / 200}{60} \approx 14.3 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#time-investment](../solution/wishocracy.qmd#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Celebrity and Influencer Endorsements {#sec-campaign_celebrity_endorsement}

**Value**: $15M

Celebrity and influencer endorsements

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Community Organizing and Ambassador Program Budget {#sec-campaign_community_organizing}

**Value**: $30M

Community organizing and ambassador program budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Contingency Fund for Unexpected Costs {#sec-campaign_contingency}

**Value**: $50M

Contingency fund for unexpected costs

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Defense Industry Conversion Program {#sec-campaign_defense_conversion}

**Value**: $50M

Defense industry conversion program

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Budget for Co-Opting Defense Industry Lobbyists {#sec-campaign_defense_lobbyist_budget}

**Value**: $50M

Budget for co-opting defense industry lobbyists

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Healthcare Industry Alignment and Partnerships {#sec-campaign_healthcare_alignment}

**Value**: $35M

Healthcare industry alignment and partnerships

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Operational Infrastructure {#sec-campaign_infrastructure}

**Value**: $20M

Campaign operational infrastructure

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## AI-Assisted Legal Work Budget {#sec-campaign_legal_ai_budget}

**Value**: $50M

AI-assisted legal work budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Legal Defense Fund {#sec-campaign_legal_defense}

**Value**: $20M

Legal defense fund

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Legal Drafting and Compliance Work {#sec-campaign_legal_work}

**Value**: $60M

Legal drafting and compliance work

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## EU Lobbying Campaign Budget {#sec-campaign_lobbying_eu}

**Value**: $40M

EU lobbying campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## G20 Countries Lobbying Budget {#sec-campaign_lobbying_g20_millions}

**Value**: $35M

G20 countries lobbying budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## US Lobbying Campaign Budget {#sec-campaign_lobbying_us}

**Value**: $50M

US lobbying campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum Mass Media Campaign Budget {#sec-campaign_media_budget_max}

**Value**: $1.00B

Maximum mass media campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Mass Media Campaign Budget {#sec-campaign_media_budget_min}

**Value**: $500M

Minimum mass media campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Opposition Research and Rapid Response {#sec-campaign_opposition_research}

**Value**: $25M

Opposition research and rapid response

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Phase 1 Campaign Budget {#sec-campaign_phase1_budget}

**Value**: $200M

Phase 1 campaign budget (Foundation, Year 1)

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Phase 2 Campaign Budget {#sec-campaign_phase2_budget}

**Value**: $500M

Phase 2 campaign budget (Scale & Momentum, Years 2-3)

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Pilot Program Testing in Small Countries {#sec-campaign_pilot_programs}

**Value**: $30M

Pilot program testing in small countries

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Voting Platform and Technology Development {#sec-campaign_platform_development}

**Value**: $35M

Voting platform and technology development

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Compliance and Navigation {#sec-campaign_regulatory_navigation}

**Value**: $20M

Regulatory compliance and navigation

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Scaling Preparation and Blueprints {#sec-campaign_scaling_prep}

**Value**: $30M

Scaling preparation and blueprints

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Core Team Staff Budget {#sec-campaign_staff_budget}

**Value**: $40M

Campaign core team staff budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Super PAC Campaign Expenditures {#sec-campaign_super_pac_budget}

**Value**: $30M

Super PAC campaign expenditures

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Tech Industry Partnerships and Infrastructure {#sec-campaign_tech_partnerships}

**Value**: $25M

Tech industry partnerships and infrastructure

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Post-Victory Treaty Implementation Support {#sec-campaign_treaty_implementation}

**Value**: $40M

Post-victory treaty implementation support

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Viral Marketing Content Creation Budget {#sec-campaign_viral_content_budget}

**Value**: $40M

Viral marketing content creation budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Weekly Advertising Cost for Campaigns {#sec-campaign_weekly_ad_cost_k}

**Value**: $500K

Weekly advertising cost for campaigns

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Cost of Unpaid Caregiving {#sec-caregiver_cost_annual}

**Value**: $6.00K

Annual cost of unpaid caregiving (replacement cost method)

*Formula*: `HOURS_PER_MONTH Ã— 12 Ã— VALUE_PER_HOUR`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Average Caregiver Hours per Month {#sec-caregiver_hours_per_month_avg}

**Value**: 110

Average caregiver hours per month

*Formula*: `HOURS_PER_WEEK Ã— 4.33`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Combined Peace and Health Dividends for ROI Calculation {#sec-combined_peace_health_dividends_annual_for_roi_calc}

**Value**: $164B

Combined peace and health dividends for ROI calculation

$$
Combined = \$113.55B + \$50B = \$163.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#combined-dividends](../appendix/1-percent-treaty-cost-effectiveness.qmd#combined-dividends)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Actual Completed Trials Multiplier {#sec-completed_trials_multiplier_actual}

**Value**: 180

Actual completed trials multiplier (180x theoretical)

**Methodology**: [../appendix/research-acceleration-model.qmd#total-multiplier](../appendix/research-acceleration-model.qmd#total-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Completed Trials Multiplier Accounting for Scale-Up {#sec-completed_trials_multiplier_conservative}

**Value**: 115

Conservative completed trials multiplier accounting for scale-up

$$
Multiplier_{conservative} = 115
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#conservative-multiplier](../appendix/research-acceleration-model.qmd#conservative-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Theoretical Maximum Research Capacity Multiplier (Maximum) {#sec-completed_trials_multiplier_theoretical_max}

**Value**: 560

Theoretical maximum research capacity multiplier (25Ã—10Ã—1.6Ã—1.4)

*Formula*: `RECRUITMENT_SPEED Ã— COMPLETION_SPEED Ã— COMPLETION_RATE Ã— FUNDING`

**Methodology**: [../appendix/research-acceleration-model.qmd#theoretical-maximum](../appendix/research-acceleration-model.qmd#theoretical-maximum)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Trial Completion Rate Improvement {#sec-completion_rate_improvement_multiplier}

**Value**: 1.6

Completion rate improvement (1.6x from 60% â†’ 95%)

$$
Completion_{mult} = \frac{0.95}{0.60} = 1.58 \approx 1.6
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#completion-rates](../appendix/research-acceleration-model.qmd#completion-rates)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Scenario ROI {#sec-conservative_scenario_roi}

**Value**: 189

Conservative scenario ROI (net benefit Ã· total costs)

$$
ROI_{conservative} = \$74.6B / \$0.393B = 190:1
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Preventable Deaths per Second from Curable Diseases {#sec-cost_of_delay_deaths_per_second}

**Value**: 1.74

Preventable deaths per second from curable diseases

$$
Delay_{deaths} = \frac{150,000}{86,400} \approx 1.74
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-of-delay](../problem/cost-of-war.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## QALY-Days Lost per Second of Inaction {#sec-cost_of_delay_qaly_days_per_second}

**Value**: 0.00644

QALY-days lost per second of inaction

$$
Delay_{QALY} = \frac{925,610 / 365}{31,557,600} \approx 0.00008
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-of-delay](../problem/cost-of-war.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Current Completed Trials per Year {#sec-current_completed_trials_per_year}

**Value**: 1,980

Current completed trials per year (trials Ã— completion rate)

$$
Completed_{current} = 3,300 \times 0.60 = 1,980
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#current-capacity](../appendix/research-acceleration-model.qmd#current-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Daily Cost of Global Healthcare System Inefficiency {#sec-daily_cost_inefficiency}

**Value**: $327M

Daily cost of healthcare system inefficiency

**Methodology**: [../solution/dfda.qmd#cost-of-delay](../solution/dfda.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Mid-Range Funding for Commercial Dct Platform {#sec-dct_platform_funding_medium}

**Value**: $500M

Mid-range funding for commercial DCT platform

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#analogous-rom](../appendix/dfda-cost-benefit-analysis.qmd#analogous-rom)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Deaths from Curable Diseases During Reading One Section {#sec-deaths_during_reading_section}

**Value**: 410

Deaths from curable diseases during reading one section

**Methodology**: [../solution/dfda.qmd#cost-of-delay](../solution/dfda.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Misallocation Factor for Spending on Death vs Prevention {#sec-death_spending_misallocation_factor}

**Value**: 1,750

Misallocation factor for spending on death vs prevention

**Methodology**: [../problem/cost-of-war.qmd#misallocation](../problem/cost-of-war.qmd#misallocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Active Trials at Any Given Time {#sec-dfda_active_trials}

**Value**: 200K

Active trials at any given time (3-12 month duration)

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual dFDA Operational Costs {#sec-dfda_annual_opex}

**Value**: $40M

Total annual dFDA operational costs (sum of all components: $15M + $10M + $8M + $5M + $2M)

$$
OPEX_{total} = \sum_{i=1}^{5} OPEX_i = 0.015 + 0.010 + 0.008 + 0.005 + 0.002
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Economic Value of Regulatory Delay Costs Avoided by dFDA {#sec-dfda_avoided_regulatory_delay_cost_annual}

**Value**: $8.10T

Annual economic value of regulatory delay costs avoided by dFDA

$$
Value_{avoided} = 74M \times \$150k = \$11.1T
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual DALYs Saved by dFDA Eliminating Regulatory Efficacy Lag {#sec-dfda_avoided_regulatory_delay_dalys_annual}

**Value**: 54M

Annual DALYs saved by dFDA eliminating regulatory efficacy lag

$$
DALY_{avoided} = 77.9M \times 0.95 = 74M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Completed Trials per Year {#sec-dfda_completed_trials_per_year}

**Value**: 361K

dFDA completed trials per year (capacity Ã— completion rate)

$$
Completed_{dFDA} = 380,000 \times 0.95 = 361,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Optimistic Drug Approvals Estimate (High Estimate) {#sec-dfda_drug_approvals_per_year_high}

**Value**: 2,000

Optimistic drug approvals estimate (40x current)

$$
Approvals_{high} = 50 \times 40 = 2,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#approval-projections](../appendix/research-acceleration-model.qmd#approval-projections)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Conservative Drug Approvals Estimate (Low Estimate) {#sec-dfda_drug_approvals_per_year_low}

**Value**: 1,000

Conservative drug approvals estimate (20x current)

$$
Approvals_{low} = 50 \times 20 = 1,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#approval-projections](../appendix/research-acceleration-model.qmd#approval-projections)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Global Eligible Patients with Minimal Exclusions {#sec-dfda_eligible_patients_global}

**Value**: 1.20B

Global eligible patients with minimal exclusions

$$
Eligible_{dFDA} = 2.4B \times 0.50 = 1.2B
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#eligible-population](../appendix/research-acceleration-model.qmd#eligible-population)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Infrastructure ICER per QALY {#sec-dfda_icer_per_qaly}

**Value**: $-674

dFDA Infrastructure ICER per QALY (net incremental cost Ã· QALYs gained)

$$
\text{ICER} = \frac{\text{Net Incremental Cost (Annual)}}{\text{QALYs Gained (Annual)}} = \frac{-\$49.96\text{B}}{74.15M \text{ QALYs}} = -\$674 \text{ per QALY}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis](../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Months to Recruit 10,000+ Patients in dFDA System {#sec-dfda_large_trial_recruitment_months}

**Value**: 3

Months to recruit 10,000+ patients in dFDA system

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-speed](../appendix/research-acceleration-model.qmd#recruitment-speed)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Large dFDA Pragmatic Trial Size {#sec-dfda_large_trial_size}

**Value**: 10,000

Large dFDA pragmatic trial size

**Methodology**: [../appendix/research-acceleration-model.qmd#trial-sizes](../appendix/research-acceleration-model.qmd#trial-sizes)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Lives Saved by dFDA {#sec-dfda_lives_saved_annual}

**Value**: 2.12M

Annual lives saved by dFDA (QALYs Ã· QALYs per life)

$$
Lives_{dFDA} = 74.15M \div 35 = 2.12M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#expected-impact](../appendix/regulatory-mortality-analysis.qmd#expected-impact)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Daily Lives Saved by dFDA {#sec-dfda_lives_saved_daily}

**Value**: 5,804

Daily lives saved by dFDA

$$
Lives_{daily} = 2.12M \div 365 = 5,808
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#expected-impact](../appendix/regulatory-mortality-analysis.qmd#expected-impact)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Net Incremental Cost for dFDA {#sec-dfda_net_incremental_cost_annual}

**Value**: $-50B

Net incremental cost for dFDA (operational costs minus R&D savings)

$$
NetCost = \$0.040B - \$50.0B = -\$49.96B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#net-incremental-cost](../appendix/dfda-cost-benefit-analysis.qmd#net-incremental-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Annual Net Savings {#sec-dfda_net_savings_annual}

**Value**: $50B

Annual net savings (gross savings minus operational costs)

$$
Savings_{net} = \$50B - \$0.04B = \$49.96B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#net-savings](../appendix/dfda-cost-benefit-analysis.qmd#net-savings)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Years to Reach Full dFDA Adoption {#sec-dfda_npv_adoption_ramp_years}

**Value**: 5

Years to reach full dFDA adoption

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#adoption-curve](../appendix/dfda-cost-benefit-analysis.qmd#adoption-curve)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Core Platform Annual OPEX {#sec-dfda_npv_annual_opex}

**Value**: $18.9M

dFDA core platform annual opex (midpoint of $11-26.5M)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Total NPV Annual OPEX {#sec-dfda_npv_annual_opex_total}

**Value**: $40M

Total NPV annual opex (dFDA core + DIH initiatives)

$$
C_{op} = \$0.01895B + \$0.02110B = \$0.04005B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## NPV of dFDA Benefits with 5-Year Adoption Ramp {#sec-dfda_npv_benefit}

**Value**: $249B

NPV of dFDA benefits with 5-year adoption ramp (10-year horizon)

$$
PV_{benefits} = \sum_{t=1}^{10} \frac{NetSavings \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-benefit](../appendix/dfda-cost-benefit-analysis.qmd#npv-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative NPV Benefit from dFDA R&D Savings {#sec-dfda_npv_net_benefit_conservative}

**Value**: $249B

Conservative NPV benefit from dFDA R&D savings (10-year discounted with adoption ramp)

$$
Benefit_{NPV} = \sum_{t=1}^{10} \frac{NetSavings \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-net-benefit](../appendix/dfda-cost-benefit-analysis.qmd#npv-net-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Present Value of Annual OPEX Over 10 Years {#sec-dfda_npv_pv_annual_opex}

**Value**: $269M

Present value of annual opex over 10 years (NPV formula)

$$
PV_{opex} = \$0.04005B \times \frac{1 - 1.08^{-10}}{0.08} \approx \$0.269B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-calculation](../appendix/dfda-cost-benefit-analysis.qmd#npv-calculation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Total NPV Cost {#sec-dfda_npv_total_cost}

**Value**: $538M

Total NPV cost (upfront + PV of annual opex)

$$
TotalCost_{NPV} = \$0.26975B + \$0.269B \approx \$0.54B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-total-cost](../appendix/dfda-cost-benefit-analysis.qmd#npv-total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Core Platform Build Cost {#sec-dfda_npv_upfront_cost}

**Value**: $40M

dFDA core platform build cost

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Total NPV Upfront Costs {#sec-dfda_npv_upfront_cost_total}

**Value**: $270M

Total NPV upfront costs (dFDA core + DIH initiatives)

$$
C_0 = \$0.040B + \$0.22975B = \$0.26975B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Community Support Costs {#sec-dfda_opex_community}

**Value**: $2.00M

dFDA community support costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Infrastructure Costs {#sec-dfda_opex_infrastructure}

**Value**: $8.00M

dFDA infrastructure costs (cloud, security)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Platform Maintenance Costs {#sec-dfda_opex_platform_maintenance}

**Value**: $15M

dFDA platform maintenance costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Regulatory Coordination Costs {#sec-dfda_opex_regulatory}

**Value**: $5.00M

dFDA regulatory coordination costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Staff Costs {#sec-dfda_opex_staff}

**Value**: $10M

dFDA staff costs (minimal, AI-assisted)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Monetized Value of dFDA QALYs {#sec-dfda_qalys_monetized}

**Value**: $11.1T

Monetized value of dFDA QALYs (QALYs Ã— economic value)

$$
Value_{QALY} = 74.15M \times \$150,000 = \$11.12T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Monetized Value of Comprehensive dFDA Benefits Including Regulatory Delay Avoidance {#sec-dfda_qalys_with_regulatory_avoidance_monetized}

**Value**: $8.12T

Monetized value of comprehensive dFDA benefits including regulatory delay avoidance

$$
Value_{total} = 74.14M \times \$150k = \$11.12T
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Annual Gross R&D Savings from Trial Cost Reduction {#sec-dfda_rd_gross_savings_annual}

**Value**: $50B

Annual gross R&D savings from trial cost reduction

$$
Savings_{gross} = \$100B \times 0.50 = \$50B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction](../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Fraction of Regulatory Delay Eliminated by dFDA Provisional Access Post-Phase I {#sec-dfda_regulatory_delay_avoidance_fraction}

**Value**: 95%

Fraction of regulatory delay eliminated by dFDA provisional access post-Phase I

$$
Avoidance = 8.2 \div (8.2 + 2.3) \approx 0.78 \text{ (use 0.95 conservatively)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Annual Value of Eliminating Delay Deaths Only, Excluding Innovation Loss {#sec-dfda_regulatory_delay_dlag_only_annual}

**Value**: $4.05T

Annual value of eliminating delay deaths only (D_lag), excluding innovation loss (D_void)

$$
D_{lag} = \$11.1T \times 0.5 \approx \$5.6T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## ROI from dFDA R&D Savings Only {#sec-dfda_roi_rd_only}

**Value**: 463

ROI from dFDA R&D savings only (10-year NPV, most conservative estimate)

$$
ROI_{RD} = \frac{\$249.3B}{\$0.54B} \approx 463
$$

**Methodology**: [../figures/dfda-roi-analysis.qmd](../figures/dfda-roi-analysis.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Recommended: ROI Including R&D Savings Plus Regulatory Delay Elimination {#sec-dfda_roi_rd_plus_delay}

**Value**: 4,990

RECOMMENDED: ROI including R&D savings plus regulatory delay elimination (D_lag only, avoids double-counting)

$$
ROI_{RD+delay} = \frac{\$1,238.6B - \$300B + \$5,555B}{\$1.0B} \approx 6,494
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd](../appendix/regulatory-mortality-analysis.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Full Impact ROI: R&D Savings Plus Regulatory Delay Elimination Plus Lost Innovation {#sec-dfda_roi_rd_plus_delay_plus_innovation}

**Value**: 8,542

Full impact ROI: R&D savings plus regulatory delay elimination plus lost innovation (D_lag + D_void)

$$
ROI_{RD+delay+innovation} = \frac{\$11,538.6B}{\$1.0B} \approx 11,539
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd](../appendix/regulatory-mortality-analysis.qmd)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Simple ROI Without NPV Adjustment {#sec-dfda_roi_simple}

**Value**: 1,250

Simple ROI without NPV adjustment (gross savings / annual opex)

$$
ROI_{simple} = \frac{\$50B}{\$0.04B} = 1,250:1
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#roi-simple](../appendix/dfda-cost-benefit-analysis.qmd#roi-simple)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Weeks to Recruit 1,000 Patients in dFDA System {#sec-dfda_small_trial_recruitment_weeks}

**Value**: 3

Weeks to recruit 1,000 patients in dFDA system

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-speed](../appendix/research-acceleration-model.qmd#recruitment-speed)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Typical dFDA Trial Size {#sec-dfda_small_trial_size}

**Value**: 1,000

Typical dFDA trial size

**Methodology**: [../appendix/research-acceleration-model.qmd#trial-sizes](../appendix/research-acceleration-model.qmd#trial-sizes)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Target Cost per Patient in USD {#sec-dfda_target_cost_per_patient_usd}

**Value**: $1.00K

Target cost per patient in USD (same as DFDA_TARGET_COST_PER_PATIENT but in dollars)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#cost-per-patient](../appendix/dfda-cost-benefit-analysis.qmd#cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Maximum Trials per Year Possible with 115x Acceleration {#sec-dfda_trials_per_year_capacity}

**Value**: 380K

Maximum trials per year possible with 115x acceleration

$$
Trials_{dFDA} = 3,300 \times 115 = 379,500 \approx 380,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Platform One-Time Build Cost {#sec-dfda_upfront_build}

**Value**: $40M

dFDA platform one-time build cost (central estimate)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#build-costs](../appendix/dfda-cost-benefit-analysis.qmd#build-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Platform One-Time Build Cost (Maximum) {#sec-dfda_upfront_build_max}

**Value**: $46M

dFDA platform one-time build cost (high estimate)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#build-costs](../appendix/dfda-cost-benefit-analysis.qmd#build-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Estimated One-Time Payment for Diabetes Cure {#sec-diabetes_cure_payment_estimate}

**Value**: $10K

Estimated one-time payment for diabetes cure

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## DIH Broader Initiatives Annual OPEX {#sec-dih_npv_annual_opex_initiatives}

**Value**: $21.1M

DIH broader initiatives annual opex (medium case)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## DIH Broader Initiatives Upfront Cost {#sec-dih_npv_upfront_cost_initiatives}

**Value**: $230M

DIH broader initiatives upfront cost (medium case)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Patients Fundable Annually {#sec-dih_patients_fundable_annually}

**Value**: 48.8M

Number of patients fundable annually at RECOVERY trial cost

$$
\$24.422B \div \$500 = 48.8M
$$

**Methodology**: [../economics/economics.qmd#funding-allocation](../economics/economics.qmd#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Clinical Trial Patient Subsidies {#sec-dih_treasury_trial_subsidies_annual}

**Value**: $24.4B

Annual clinical trial patient subsidies (all medical research funds after dFDA operations)

$$
\$24.462B - \$0.04B = \$24.422B
$$

**Methodology**: [../economics/economics.qmd#funding-allocation](../economics/economics.qmd#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Percentage of Caregiving for Treatable Disease Conditions {#sec-disease_related_caregiver_pct}

**Value**: 40%

Percentage of caregiving for treatable disease conditions (vs aging, disability, children)

**Methodology**: [Disease-Related Caregiving Analysis](#disease-related-caregiving-estimate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths {#sec-disease_vs_terrorism_deaths_ratio}

**Value**: 18,274

Ratio of annual disease deaths to 9/11 terrorism deaths

*Formula*: `ANNUAL_DISEASE_DEATHS Ã· 911_DEATHS`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Ratio of Annual Disease Deaths to War Deaths {#sec-disease_vs_war_deaths_ratio}

**Value**: 1.63

Ratio of annual disease deaths to war deaths

*Formula*: `ANNUAL_DISEASE_DEATHS Ã· WAR_DEATHS`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Coverage Factor of Treaty Funding vs dFDA OPEX {#sec-dividend_coverage_factor}

**Value**: 680

Coverage factor of treaty funding vs dFDA opex (sustainability margin)

$$
Coverage = \$27.18B / \$0.04B = 679x
$$

**Methodology**: [../strategy/roadmap.qmd#sustainability](../strategy/roadmap.qmd#sustainability)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## High Estimate of Annual Savings from Drug Price Reductions {#sec-drug_price_reduction_savings_high}

**Value**: $180B

High estimate of annual savings from drug price reductions (50% reduction of $360B U.S. spending)

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Low Estimate of Annual Savings from Drug Price Reductions {#sec-drug_price_reduction_savings_low}

**Value**: $72B

Low estimate of annual savings from drug price reductions (20% reduction of $360B U.S. spending)

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate from Treaty Participation {#sec-effective_hourly_rate}

**Value**: $292K

Effective hourly rate from treaty participation

$$
HourlyRate = \frac{\$4,300,000}{14.75} \approx \$291,525/hr
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lifetime Benefit for Age 30 Baseline Scenario {#sec-effective_hourly_rate_lifetime_benefit}

**Value**: $4.30M

Lifetime benefit for age 30 baseline scenario ($4.3M)

$$
Benefit = \$4,300,000
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Rate Multiplier vs CEO Rate {#sec-effective_hourly_rate_vs_ceo_multiplier}

**Value**: 29.2

Effective rate multiplier vs CEO rate

$$
Multiplier = \frac{\$291,525}{\$10,000} \approx 29x
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Rate Multiplier vs Average US Wage {#sec-effective_hourly_rate_vs_wage_multiplier}

**Value**: 9,744

Effective rate multiplier vs average US wage

$$
Multiplier = \frac{\$291,525}{\$30} \approx 9,718x
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected ROI for dFDA Accounting for 10% Political Success Probability (Conservative) {#sec-expected_roi_conservative_dfda}

**Value**: 46.3

Expected ROI for dFDA accounting for 10% political success probability

$$
E[ROI]_{\text{conservative}} = 463 \times 0.10 = 46.3
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected ROI for dFDA Accounting for 25% Political Success Probability {#sec-expected_roi_moderate_dfda}

**Value**: 116

Expected ROI for dFDA accounting for 25% political success probability

$$
E[ROI]_{\text{moderate}} = 463 \times 0.25 = 115.8
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected ROI for dFDA Accounting for 50% Political Success Probability (Optimistic) {#sec-expected_roi_optimistic_dfda}

**Value**: 232

Expected ROI for dFDA accounting for 50% political success probability

$$
E[ROI]_{\text{optimistic}} = 463 \times 0.50 = 231.5
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Investment for Family Offices {#sec-family_office_investment_min}

**Value**: $5.00M

Minimum investment for family offices

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Nonprofit Foundation Funding in Base Case Scenario {#sec-foundation_funding_base_case}

**Value**: $442M

Nonprofit foundation funding in base case scenario (health R&D, civic infrastructure)

$$
Foundation_{base} = \$940M \times 47\% = \$442M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding as Percentage of Total Campaign Cost {#sec-foundation_funding_percentage}

**Value**: 51%

Foundation funding as percentage of total campaign cost (realistic scenario)

$$
Foundation\% = \frac{\$519M}{\$1,020M} = 51\%
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Nonprofit Foundation Funding in Realistic Scenario {#sec-foundation_funding_realistic}

**Value**: $519M

Nonprofit foundation funding in realistic scenario (health R&D, civic infrastructure)

$$
Foundation_{realistic} = \$1,020M \times 51\% = \$519M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Nonprofit Foundation Funding in Worst-Case Scenario {#sec-foundation_funding_worst_case}

**Value**: $542M

Nonprofit foundation funding in worst-case scenario (health R&D, civic infrastructure)

$$
Foundation_{worst} = \$1,206M \times 45\% = \$542M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Legal/Compliance (Realistic) {#sec-foundation_legal_compliance_realistic}

**Value**: $53M

Foundation funding for legal/compliance (international health law research)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Political Lobbying (Realistic) {#sec-foundation_lobbying_realistic}

**Value**: $0

Foundation funding for political lobbying (zero due to 501c3 restrictions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Operations (Realistic) {#sec-foundation_operations_realistic}

**Value**: $20M

Foundation funding for operations (nonprofit R&D staff)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Partnerships (Realistic) {#sec-foundation_partnerships_realistic}

**Value**: $29M

Foundation funding for partnerships (NGOs, patient advocacy, scientific institutions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Reserve (Realistic) {#sec-foundation_reserve_realistic}

**Value**: $37M

Foundation funding for reserve (nonprofit contingency)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Technology R&D (Realistic) {#sec-foundation_tech_rd_realistic}

**Value**: $226M

Foundation funding for technology R&D (dFDA platform, Wishocracy, infrastructure)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding for Viral Referendum Platform (Realistic) {#sec-foundation_viral_referendum_realistic}

**Value**: $77M

Foundation funding for viral referendum platform (biometric verification, civic infrastructure)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Conflict Deaths Globally {#sec-global_annual_conflict_deaths_total}

**Value**: 245K

Total annual conflict deaths globally (sum of combat, terror, state violence)

$$
Deaths_{total} = 233,600 + 8,300 + 2,700 = 244,600
$$

**Methodology**: [../problem/cost-of-war.qmd#death-accounting](../problem/cost-of-war.qmd#death-accounting)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Deaths from Curable Diseases Globally {#sec-global_annual_deaths_curable_diseases}

**Value**: 54.8M

Annual deaths from curable diseases globally

*Formula*: `GLOBAL_DAILY_DEATHS_CURABLE_DISEASES Ã— 365`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Cost of Combat Deaths {#sec-global_annual_human_cost_active_combat}

**Value**: $2.34T

Annual cost of combat deaths (deaths Ã— VSL)

$$
Cost_{combat} = 233,600 \times \$10M = \$2,336B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Cost of State Violence Deaths {#sec-global_annual_human_cost_state_violence}

**Value**: $27B

Annual cost of state violence deaths (deaths Ã— VSL)

$$
Cost_{state} = 2,700 \times \$10M = \$27B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Cost of Terror Deaths {#sec-global_annual_human_cost_terror_attacks}

**Value**: $83B

Annual cost of terror deaths (deaths Ã— VSL)

$$
Cost_{terror} = 8,300 \times \$10M = \$83B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Human Life Losses from Conflict {#sec-global_annual_human_life_losses_conflict}

**Value**: $2.45T

Total annual human life losses from conflict (sum of combat, terror, state violence)

$$
Cost_{human} = \$2,336B + \$83B + \$27B = \$2,446B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Infrastructure Destruction {#sec-global_annual_infrastructure_destruction_conflict}

**Value**: $1.88T

Total annual infrastructure destruction (sum of transportation, energy, communications, water, education, healthcare)

$$
Infra_{damage} = \$487.3B + \$421.7B + \$298.1B + \$267.8B + \$234.5B + \$165.6B = \$1,875B
$$

**Methodology**: [../problem/cost-of-war.qmd#infrastructure-damage](../problem/cost-of-war.qmd#infrastructure-damage)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Trade Disruption {#sec-global_annual_trade_disruption_conflict}

**Value**: $616B

Total annual trade disruption (sum of shipping, supply chain, energy prices, currency instability)

$$
Trade_{disruption} = \$247.1B + \$186.8B + \$124.7B + \$57.4B = \$616B
$$

**Methodology**: [../problem/cost-of-war.qmd#trade-disruption](../problem/cost-of-war.qmd#trade-disruption)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Direct War Costs {#sec-global_annual_war_direct_costs_total}

**Value**: $7.66T

Total annual direct war costs (military spending + infrastructure + human life + trade disruption)

$$
DirectCosts = \$2,718B + \$1,875B + \$2,446B + \$616B = \$7,655B
$$

**Methodology**: [../problem/cost-of-war.qmd#direct-costs](../problem/cost-of-war.qmd#direct-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Indirect War Costs {#sec-global_annual_war_indirect_costs_total}

**Value**: $3.70T

Total annual indirect war costs (opportunity cost + veterans + refugees + environment + mental health + lost productivity)

$$
IndirectCosts = \$2,718B + \$200.1B + \$150B + \$100B + \$232B + \$300B = \$3,700.1B
$$

**Methodology**: [../problem/cost-of-war.qmd#indirect-costs](../problem/cost-of-war.qmd#indirect-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Cost of War Worldwide {#sec-global_annual_war_total_cost}

**Value**: $11.4T

Total annual cost of war worldwide (direct + indirect costs)

$$
TotalWarCost = \$7,655B + \$3,700.1B = \$11,355.1B
$$

**Methodology**: [../problem/cost-of-war.qmd#total-cost](../problem/cost-of-war.qmd#total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost per Conflict Death {#sec-global_cost_per_conflict_death}

**Value**: $46.4M

Cost per conflict death (war cost Ã· deaths)

$$
CostPerDeath = \frac{\$11,355.1B \times 10^9}{244,600} / 10^6 \approx \$46.4M
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost per Life Saved by Medical Research {#sec-global_cost_per_life_saved_med_research_annual}

**Value**: $16.1K

Cost per life saved by medical research

$$
CostPerLifeSaved = \frac{\$67.5B \times 10^9}{4,200,000} \approx \$16,071
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual QALYs Gained from dFDA (Regulatory Delay Elimination) {#sec-global_dfda_qalys_gained_annual}

**Value**: 74.1M

Annual QALYs gained from dFDA via eliminating 7.2-year efficacy lag (PRIMARY ESTIMATE)

$$
QALYs_{dFDA} = 74.0M + 0.14M = 74.15M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#expected-impact](../appendix/regulatory-mortality-analysis.qmd#expected-impact)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual QALYs Gained from dFDA (Incremental Bottom-Up) {#sec-global_dfda_qalys_incremental}

**Value**: 840K

Annual QALYs gained from dFDA (incremental bottom-up estimate for reference only - NOT primary estimate)

**Methodology**: [../appendix/dfda-qaly-model.qmd](../appendix/dfda-qaly-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual QALYs from dFDA Including Regulatory Delay Avoidance {#sec-global_dfda_qalys_with_regulatory_avoidance}

**Value**: 54.2M

Total annual QALYs from dFDA including regulatory delay avoidance (top-down comprehensive estimate)

$$
QALYs_{total} = 74M + 140k \approx 74.14M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Economic Burden of Disease Globally {#sec-global_disease_economic_burden_annual}

**Value**: $109T

Total economic burden of disease globally (medical + productivity + mortality)

*Formula*: `MEDICAL_COSTS + PRODUCTIVITY_LOSS + MORTALITY_VALUE`

**Methodology**: [ReferenceID.DISEASE_ECONOMIC_BURDEN_109T](#ReferenceID.DISEASE_ECONOMIC_BURDEN_109T)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Per Capita Military Spending Globally {#sec-global_military_spending_per_capita_annual}

**Value**: $340

Per capita military spending globally

$$
PerCapita_{military} = \$2,718B / 8.0B = \$339.75
$$

**Methodology**: [../problem/cost-of-war.qmd#per-capita](../problem/cost-of-war.qmd#per-capita)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Military Spending After 1% Treaty Reduction {#sec-global_military_spending_post_treaty_annual_2024}

**Value**: $2.69T

Global military spending after 1% treaty reduction

$$
PostTreaty_{military} = \$2,718B \times 0.99 = \$2,690.82B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#post-treaty](../strategy/treaty-adoption-strategy.qmd#post-treaty)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Cost of War and Disease with All Externalities {#sec-global_total_health_and_war_cost_annual}

**Value**: $129T

Total annual cost of war and disease with all externalities (direct + indirect costs for both)

*Formula*: `WAR_TOTAL_COSTS + SYMPTOMATIC_TREATMENT + DISEASE_BURDEN`

**Methodology**: [../appendix/humanity-budget-overview.qmd](../appendix/humanity-budget-overview.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Per Capita Total War Cost Globally {#sec-global_total_war_cost_per_capita_annual}

**Value**: $1.42K

Per capita total war cost globally

$$
PerCapita_{war} = \$11,355.1B / 8.0B = \$1,419.39
$$

**Methodology**: [../problem/cost-of-war.qmd#per-capita](../problem/cost-of-war.qmd#per-capita)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Direct War Cost per Second Globally {#sec-global_war_direct_cost_per_second}

**Value**: $243K

Direct war cost per second globally

$$
CostPerSecond = \frac{\$7,655B \times 10^9}{31,557,600} \approx \$242,749
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-per-second](../problem/cost-of-war.qmd#cost-per-second)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Investment for High Net Worth Individuals {#sec-high_net_worth_investor_min}

**Value**: $1.00M

Minimum investment for high net worth individuals

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Investment for Institutional Investors {#sec-institutional_investor_min}

**Value**: $10M

Minimum investment for institutional investors

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lifetime War Cost per Person {#sec-lifetime_war_cost_per_capita}

**Value**: $114K

Lifetime war cost per person (80-year lifespan)

$$
Lifetime_{war} = \$1,419.39 \times 80 = \$113,551
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd#lifetime-cost](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd#lifetime-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum Bond Investment for Lobbyist Incentives {#sec-lobbyist_bond_investment_max}

**Value**: $20M

Maximum bond investment for lobbyist incentives

**Methodology**: [../strategy/roadmap.qmd#lobbyist-incentives](../strategy/roadmap.qmd#lobbyist-incentives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Bond Investment for Lobbyist Incentives {#sec-lobbyist_bond_investment_min}

**Value**: $5.00M

Minimum bond investment for lobbyist incentives

**Methodology**: [../strategy/roadmap.qmd#lobbyist-incentives](../strategy/roadmap.qmd#lobbyist-incentives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## 30-Year Savings from Longevity Therapy per Person {#sec-longevity_therapy_savings_30yr}

**Value**: $150K

30-year savings from longevity therapy per person

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Medical Research Spending as Percentage of Total Disease Burden {#sec-medical_research_pct_of_disease_burden}

**Value**: 0.0525%

Medical research spending as percentage of total disease burden

*Formula*: `MED_RESEARCH Ã· TOTAL_BURDEN`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Ratio of Military Spending to Medical Research Spending {#sec-military_vs_medical_research_ratio}

**Value**: 40.3

Ratio of military spending to medical research spending

$$
Ratio = \frac{\$2,718B}{\$67.5B} \approx 40.3:1
$$

**Methodology**: [../problem/cost-of-war.qmd#misallocation](../problem/cost-of-war.qmd#misallocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Misallocation Factor: Cost to Kill vs Cost to Save {#sec-misallocation_factor_death_vs_saving}

**Value**: 2,889

Misallocation factor: cost to kill vs cost to save

$$
Misallocation = \frac{\$46.4M}{\$16,071} \approx 2,889x
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost-Effectiveness Multiplier vs Givewell Top Charities {#sec-multiplier_vs_givewell}

**Value**: 1.71e-05

Cost-effectiveness multiplier vs GiveWell top charities

$$
Multiplier = \frac{|-\$6.19M \times 10^9|}{\$4,500} \approx 1,376x
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#givewell-comparison](../appendix/1-percent-treaty-cost-effectiveness.qmd#givewell-comparison)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foregone Economic Value per Day from Not Implementing System {#sec-opportunity_cost_per_day}

**Value**: $3.39B

Foregone economic value per day from not implementing system

*Formula*: `TREATY_COMPLETE_CASE_ANNUAL_BENEFITS Ã· 365`

**Methodology**: [../economics/economics.qmd#the-opportunity-cost-clock](../economics/economics.qmd#the-opportunity-cost-clock)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foregone Economic Value per Second from Not Implementing System {#sec-opportunity_cost_per_second}

**Value**: $39.3K

Foregone economic value per second from not implementing system

*Formula*: `TREATY_COMPLETE_CASE_ANNUAL_BENEFITS Ã— 1B Ã· SECONDS_PER_YEAR`

**Methodology**: [../economics/economics.qmd#the-opportunity-cost-clock](../economics/economics.qmd#the-opportunity-cost-clock)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Scenario ROI {#sec-optimistic_scenario_roi}

**Value**: 1,281

Optimistic scenario ROI (net benefit Ã· total costs)

$$
ROI_{optimistic} = \$294.8B / \$0.230B = 1,282:1
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Bondholder Payout in Partial Success Scenario {#sec-partial_success_bondholder_payout}

**Value**: $1.36B

Bondholder payout in partial success scenario

$$
Payout_{partial} = \$13.59B \times 0.10 = \$1.36B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## DIH Revenue in Partial Success Scenario {#sec-partial_success_dih_revenue}

**Value**: $13.6B

DIH revenue in partial success scenario

$$
Revenue_{partial} = \$2,718B \times 0.50 \times 0.01 = \$13.59B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Investor ROI in Partial Success Scenario {#sec-partial_success_investor_roi}

**Value**: 136%

Investor ROI in partial success scenario

$$
ROI_{partial} = \$1.36B / \$1B = 1.359 = 135.9\%
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Military Spending Share for Partial Success Scenario {#sec-partial_success_military_spending_share}

**Value**: 50%

Military spending share for partial success scenario (US, EU, UK)

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Research Funding in Partial Success Scenario {#sec-partial_success_research_funding}

**Value**: $12.2B

Research funding in partial success scenario

$$
Research_{partial} = \$13.59B \times 0.90 = \$12.23B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum Patient Copay for Cure {#sec-patient_cure_copay_max}

**Value**: $1.00K

Maximum patient copay for cure

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Peace Dividend from 1% Reduction in Total War Costs {#sec-peace_dividend_annual_societal_benefit}

**Value**: $114B

Annual peace dividend from 1% reduction in total war costs

$$
Peace\_Dividend = \$11,355B \times 0.01 = \$113.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-dividend](../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conflict Reduction Benefits from 1% Less Military Spending {#sec-peace_dividend_conflict_reduction}

**Value**: $86.4B

Conflict reduction benefits from 1% less military spending (lower confidence - assumes proportional relationship)

$$
PD_{conflict} = \$113.55B - \$27.18B = \$86.37B
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Direct War Costs {#sec-peace_dividend_direct_costs}

**Value**: $76.5B

Annual savings from 1% reduction in direct war costs

$$
PD_{direct} = \$7,655B \times 0.01 = \$76.55B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Direct Fiscal Savings from 1% Military Spending Reduction {#sec-peace_dividend_direct_fiscal_savings}

**Value**: $27.2B

Direct fiscal savings from 1% military spending reduction (high confidence)

$$
PD_{fiscal} = \$27.18B
$$

**Methodology**: [SIPRI Military Spending Database](#ReferenceID.SIPRI_2024_SPENDING)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Environmental Damage {#sec-peace_dividend_environmental}

**Value**: $1.00B

Annual savings from 1% reduction in environmental damage

$$
PD_{env} = \$10B \times 0.01 = \$0.10B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Human Casualties {#sec-peace_dividend_human_casualties}

**Value**: $24.5B

Annual savings from 1% reduction in human casualties

$$
PD_{human} = \$2,446B \times 0.01 = \$24.46B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Indirect War Costs {#sec-peace_dividend_indirect_costs}

**Value**: $37B

Annual savings from 1% reduction in indirect war costs

$$
PD_{indirect} = \$3,700.1B \times 0.01 = \$37.00B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Infrastructure Destruction {#sec-peace_dividend_infrastructure}

**Value**: $18.8B

Annual savings from 1% reduction in infrastructure destruction

$$
PD_{infra} = \$1,875B \times 0.01 = \$18.75B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Lost Economic Growth {#sec-peace_dividend_lost_economic_growth}

**Value**: $27.2B

Annual savings from 1% reduction in lost economic growth

$$
PD_{growth} = \$2,718B \times 0.01 = \$27.18B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Lost Human Capital {#sec-peace_dividend_lost_human_capital}

**Value**: $3.00B

Annual savings from 1% reduction in lost human capital

$$
PD_{capital} = \$30B \times 0.01 = \$0.30B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in PTSD and Mental Health Costs {#sec-peace_dividend_ptsd}

**Value**: $2.32B

Annual savings from 1% reduction in PTSD and mental health costs

$$
PD_{PTSD} = \$23.2B \times 0.01 = \$0.23B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Refugee Support Costs {#sec-peace_dividend_refugee_support}

**Value**: $1.50B

Annual savings from 1% reduction in refugee support costs

$$
PD_{refugee} = \$15B \times 0.01 = \$0.15B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Benefit per Dollar Redirected {#sec-peace_dividend_roi}

**Value**: 5.18

Total benefit per dollar redirected (savings + funding captured)

$$
ROI_{peace} = \frac{\$113.55B + \$27.18B}{\$27.18B} = 5.18
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Trade Disruption {#sec-peace_dividend_trade_disruption}

**Value**: $6.16B

Annual savings from 1% reduction in trade disruption

$$
PD_{trade} = \$616B \times 0.01 = \$6.16B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Savings from 1% Reduction in Veteran Healthcare Costs {#sec-peace_dividend_veteran_healthcare}

**Value**: $2.00B

Annual savings from 1% reduction in veteran healthcare costs

$$
PD_{veteran} = \$20.01B \times 0.01 = \$0.20B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Personal Life Extension for Age 30 Baseline from 1% Treaty {#sec-personal_life_extension_years_age_30}

**Value**: 72

Personal life extension for age 30 baseline from 1% Treaty (72 extra years)

$$
LifeExtension = 72 \text{ years}
$$

**Methodology**: [../call-to-action/your-personal-benefits.qmd](../call-to-action/your-personal-benefits.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## US Per Capita Chronic Disease Cost {#sec-per_capita_chronic_disease_cost}

**Value**: $12.2K

US per capita chronic disease cost

*Formula*: `US_CHRONIC_DISEASE_SPENDING Ã· US_POPULATION`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## US Per Capita Mental Health Cost {#sec-per_capita_mental_health_cost}

**Value**: $1.04K

US per capita mental health cost

*Formula*: `US_MENTAL_HEALTH_COST Ã· US_POPULATION`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Pharma Payment per Cured Patient in 50/50 Model {#sec-pharma_cure_payment_per_patient}

**Value**: $90K

Pharma payment per cured patient in 50/50 model

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## System Profit per Life Saved {#sec-profit_per_life_saved}

**Value**: $168K

System profit per life saved (specific calculation)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Base Case QALYs from Faster Drug Access {#sec-qalys_from_faster_access}

**Value**: 200K

Base case QALYs from faster drug access

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative QALYs from Faster Access {#sec-qalys_from_faster_access_conservative}

**Value**: 90,000

Conservative QALYs from faster access (15 drugs/yr Ã— 1 yr accel Ã— 6k QALYs/drug)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic QALYs from Faster Drug Access {#sec-qalys_from_faster_access_optimistic}

**Value**: 500K

Optimistic QALYs from faster drug access

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Base Case QALYs from Enabling New Therapies for Rare/Untreatable Diseases {#sec-qalys_from_new_therapies}

**Value**: 500K

Base case QALYs from enabling new therapies for rare/untreatable diseases

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative QALYs from New Therapies {#sec-qalys_from_new_therapies_conservative}

**Value**: 50,000

Conservative QALYs from new therapies (5 therapies/yr Ã— 2k patients Ã— 5 QALYs/patient)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic QALYs from New Therapies {#sec-qalys_from_new_therapies_optimistic}

**Value**: 3.00M

Optimistic QALYs from new therapies

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Base Case QALYs from Better Prevention Through Real-World Data {#sec-qalys_from_prevention}

**Value**: 140K

Base case QALYs from better prevention through real-world data

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative QALYs from Prevention {#sec-qalys_from_prevention_conservative}

**Value**: 50,000

Conservative QALYs from prevention (5M patients Ã— 0.01 QALYs/patient)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic QALYs from Prevention {#sec-qalys_from_prevention_optimistic}

**Value**: 150K

Optimistic QALYs from prevention

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Conservative QALYs {#sec-qalys_total_conservative}

**Value**: 190K

Total conservative QALYs (90k + 50k + 50k)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Optimistic QALYs {#sec-qalys_total_optimistic}

**Value**: 3.65M

Total optimistic QALYs (500k + 150k + 3M)

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Investment for Qualified Investors {#sec-qualified_investor_min}

**Value**: $100K

Minimum investment for qualified investors

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Recruitment Speed Multiplier {#sec-recruitment_speed_multiplier}

**Value**: 25

Recruitment speed multiplier (25x faster from 2% â†’ 50% eligibility)

$$
Recruitment_{mult} = \frac{0.50}{0.002} = 25
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-acceleration](../appendix/research-acceleration-model.qmd#recruitment-acceleration)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Global Lost Refugee Productivity {#sec-refugee_lost_productivity_global_total}

**Value**: $2.54T

Total global lost refugee productivity

$$
RefugeeLosses = \frac{108.4M \times \$23,400}{10^9} = \$2,536.6B
$$

**Methodology**: [../problem/cost-of-war.qmd#refugee-costs](../problem/cost-of-war.qmd#refugee-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual DALYs Lost to Regulatory Delay Under Current System {#sec-regulatory_delay_annual_dalys}

**Value**: 56.9M

Annual DALYs lost to regulatory delay under current system

$$
DALY_{annual} = 3.526B \div 62 = 56.87M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annualized Economic Loss from Regulatory Delay {#sec-regulatory_delay_annual_loss}

**Value**: $8.53T

Annualized economic loss from regulatory delay

$$
Annual_{loss} = 56.87M \times \$150k = \$8.53T/year
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Disability-Adjusted Life Years Lost to Regulatory Delay {#sec-regulatory_delay_dalys}

**Value**: 3,526

Total Disability-Adjusted Life Years lost to regulatory delay (1962-2024)

$$
DALY_{total} = YLL + YLD = 3.14B + 0.388B = 3.526B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Deaths from Regulatory Delay Under Current System {#sec-regulatory_delay_deaths_annual}

**Value**: 2.98M

Annual deaths from regulatory delay under current system (annualized from 1962-2024)

$$
Deaths_{annual} = 184.6M \div 62 = 2.98M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Daily Deaths from Regulatory Delay Under Current System {#sec-regulatory_delay_deaths_daily}

**Value**: 8,157

Daily deaths from regulatory delay under current system

$$
Deaths_{daily} = 2.98M \div 365 = 8,164
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lower Bound Excess Deaths from Regulatory Delay {#sec-regulatory_delay_deaths_lower_bound}

**Value**: 110

Lower bound excess deaths from regulatory delay (1962-2024, steel-man scenario)

$$
D_{total}^{lower} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence â€¢ âš–ï¸ Conservative estimate*

:::

::: {.callout-note icon=false collapse=false}
## Mean Estimate Excess Deaths from Regulatory Delay {#sec-regulatory_delay_deaths_mean}

**Value**: 185

Mean estimate excess deaths from regulatory delay (1962-2024)

$$
D_{total}^{mean} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Upper Bound Excess Deaths from Regulatory Delay {#sec-regulatory_delay_deaths_upper_bound}

**Value**: 318

Upper bound excess deaths from regulatory delay (1962-2024, linear innovation trajectory)

$$
D_{total}^{upper} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cumulative Economic Deadweight Loss from Regulatory Delay {#sec-regulatory_delay_economic_loss}

**Value**: $529T

Cumulative economic deadweight loss from regulatory delay (1962-2024, 2024 USD)

$$
DWL = 3.526B \times \$150k = \$528.9T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Years Lived with Disability During Regulatory Delay {#sec-regulatory_delay_yld}

**Value**: 388

Years Lived with Disability during regulatory delay

$$
YLD = 184.6M \times 6 \times 0.35 = 387.66M = 0.388B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Years of Life Lost from Regulatory Delay Deaths {#sec-regulatory_delay_yll}

**Value**: 3,138

Years of Life Lost from regulatory delay deaths

$$
YLL = 184.6M \times (79 - 62) = 3.14B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Research Capacity Multiplier from dFDA {#sec-research_acceleration_multiplier}

**Value**: 115

Total research capacity multiplier from dFDA

$$
Multiplier = 1.40 \times 82 = 115
$$

**Methodology**: [../appendix/research-acceleration-model.qmd](../appendix/research-acceleration-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## 1% Treaty ROI at 1% Discount Rate {#sec-roi_discount_1pct}

**Value**: 532

ROI at 1% discount rate (approximate 15% increase from 3% baseline)

$$
ROI_{1\%} \approx 463 \times 1.15 = 532
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## 1% Treaty ROI at 3% Discount Rate {#sec-roi_discount_3pct}

**Value**: 463

ROI at 3% discount rate (baseline)

$$
ROI_{3\%} = 463
$$

**Methodology**: [Direct Calculation](#calculated)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## 1% Treaty ROI at 5% Discount Rate {#sec-roi_discount_5pct}

**Value**: 407

ROI at 5% discount rate (approximate 12% decrease from 3% baseline)

$$
ROI_{5\%} \approx 463 \times 0.88 = 407
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## 1% Treaty ROI at 7% Discount Rate {#sec-roi_discount_7pct}

**Value**: 361

ROI at 7% discount rate (approximate 22% decrease from 3% baseline)

$$
ROI_{7\%} \approx 463 \times 0.78 = 361
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Campaign Cost {#sec-sensitivity_campaign_cost_conservative}

**Value**: $333M

Conservative campaign cost (3-year amortization)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Campaign Cost {#sec-sensitivity_campaign_cost_optimistic}

**Value**: $200M

Optimistic campaign cost (5-year amortization)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Central Cost per Life Saved {#sec-sensitivity_cost_per_life_central}

**Value**: $-7

Central cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Cost per Life Saved {#sec-sensitivity_cost_per_life_conservative}

**Value**: $-6

Conservative cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Cost per Life Saved {#sec-sensitivity_cost_per_life_optimistic}

**Value**: $-5

Optimistic cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative dFDA Operational Costs {#sec-sensitivity_dfda_opex_conservative}

**Value**: $60M

Conservative dFDA operational costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic dFDA Operational Costs {#sec-sensitivity_dfda_opex_optimistic}

**Value**: $30M

Optimistic dFDA operational costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative dFDA Savings Estimate {#sec-sensitivity_dfda_savings_conservative}

**Value**: $25B

Conservative dFDA savings estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic dFDA Savings Estimate {#sec-sensitivity_dfda_savings_optimistic}

**Value**: $95B

Optimistic dFDA savings estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Central ICER from Sensitivity Analysis {#sec-sensitivity_icer_central}

**Value**: $-187K

Central ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative ICER from Sensitivity Analysis {#sec-sensitivity_icer_conservative}

**Value**: $-171K

Conservative ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic ICER from Sensitivity Analysis {#sec-sensitivity_icer_optimistic}

**Value**: $-137K

Optimistic ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Central Scenario Lives Saved {#sec-sensitivity_lives_saved_central}

**Value**: 2.12M

Central scenario lives saved (total QALYs Ã· QALYs/life)

$$
Lives_{central} = 925,610 / 35 \approx 26,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Net Benefit from Sensitivity Analysis {#sec-sensitivity_net_benefit_conservative}

**Value**: $74.6B

Conservative net benefit from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Net Benefit from Sensitivity Analysis {#sec-sensitivity_net_benefit_optimistic}

**Value**: $295B

Optimistic net benefit from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Peace Dividend Estimate {#sec-sensitivity_peace_dividend_conservative}

**Value**: $50B

Conservative peace dividend estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Peace Dividend Estimate {#sec-sensitivity_peace_dividend_optimistic}

**Value**: $200B

Optimistic peace dividend estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Peace QALYs {#sec-sensitivity_peace_qalys_conservative}

**Value**: 17,500

Conservative peace QALYs (500 lives Ã— 35 QALYs/life)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Peace QALYs {#sec-sensitivity_peace_qalys_optimistic}

**Value**: 52,500

Optimistic peace QALYs (1,500 lives Ã— 35 QALYs/life)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Total Benefits Estimate {#sec-sensitivity_total_benefits_conservative}

**Value**: $75B

Conservative total benefits estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Total Benefits Estimate {#sec-sensitivity_total_benefits_optimistic}

**Value**: $295B

Optimistic total benefits estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Total Costs {#sec-sensitivity_total_costs_conservative}

**Value**: $393M

Conservative total costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Total Costs {#sec-sensitivity_total_costs_optimistic}

**Value**: $230M

Optimistic total costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Total QALYs {#sec-sensitivity_total_qalys_conservative}

**Value**: 208K

Conservative total QALYs (peace + dFDA)

$$
QALYs_{conservative} = 17,500 + 190,000 = 207,500
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Total QALYs {#sec-sensitivity_total_qalys_optimistic}

**Value**: 3.70M

Optimistic total QALYs (peace + dFDA)

$$
QALYs_{optimistic} = 52,500 + 3,650,000 = 3,702,500
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Simultaneous Trials Capacity Multiplier {#sec-simultaneous_trials_multiplier}

**Value**: 20

Simultaneous trials multiplier (20x more trials)

**Methodology**: [../appendix/research-acceleration-model.qmd#capacity-multiplier](../appendix/research-acceleration-model.qmd#capacity-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum Target Participant Count for Social Media Campaigns {#sec-social_media_participant_target_max}

**Value**: 2,000

Maximum target participant count for social media campaigns

**Methodology**: [../strategy/viral-marketing.qmd](../strategy/viral-marketing.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Target Participant Count for Social Media Campaigns {#sec-social_media_participant_target_min}

**Value**: 500

Minimum target participant count for social media campaigns

**Methodology**: [../strategy/viral-marketing.qmd](../strategy/viral-marketing.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA System Profit per Life Saved {#sec-system_profit_per_life_saved}

**Value**: $5.87M

System profit per life saved in millions

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Words in the Book {#sec-total_book_words}

**Value**: 171K

Total words in the book

**Methodology**: [Book Word Count Analysis](#book-word-count)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Global Research Funding (Baseline + 1% Treaty Funding) {#sec-total_research_funding_with_treaty}

**Value**: $94.7B

Total global research funding (baseline + 1% treaty funding)

$$
\$67.5B + \$27.18B = \$94.68B
$$

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Time Investment in Treaty Participation {#sec-total_time_investment_hours}

**Value**: 14.7

Total time investment (reading + actions)

$$
TotalInvestment = 14.3 + 0.45 = 14.75 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#time-investment](../solution/wishocracy.qmd#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Ratio of Total War Cost to WHO Budget {#sec-total_war_cost_to_who_budget_ratio}

**Value**: 168

Ratio of total war cost to WHO budget (168x)

**Methodology**: [../problem/cost-of-war.qmd](../problem/cost-of-war.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Target Years to Market with dFDA {#sec-treatment_acceleration_years_target}

**Value**: 2

Target years to market with dFDA

**Methodology**: [../appendix/research-acceleration-model.qmd#target-timeline](../appendix/research-acceleration-model.qmd#target-timeline)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Hours of Human Suffering Eliminated by 1% Treaty {#sec-treaty_annual_suffering_hours_eliminated}

**Value**: 9100B

Annual hours of human suffering eliminated by 1% Treaty (9.1 trillion hours)

$$
Suffering = 9.1T \text{ hours annually}
$$

**Methodology**: [../economics/economics.qmd#suffering-reduction](../economics/economics.qmd#suffering-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty System Benefit Multiplier vs Childhood Vaccination Programs {#sec-treaty_benefit_multiplier_vs_vaccines}

**Value**: 10.9

Treaty system benefit multiplier vs childhood vaccination programs

*Formula*: `TREATY_CONSERVATIVE_BENEFIT Ã· CHILDHOOD_VACCINATION_BENEFIT`

**Methodology**: [../economics/economics.qmd#better-than-the-best-charities](../economics/economics.qmd#better-than-the-best-charities)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Amortized Annual Treaty Campaign Cost {#sec-treaty_campaign_annual_cost_amortized}

**Value**: $250M

Amortized annual campaign cost (total cost Ã· campaign duration)

$$
AnnualCost = \$1B / 4 = \$0.25B
$$

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Budget for Mass Mobilization {#sec-treaty_campaign_budget_mass_bribery}

**Value**: $140M

Campaign budget for mass mobilization (voting bloc build)

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Budget for Super Pacs and Political Lobbying {#sec-treaty_campaign_budget_super_pacs}

**Value**: $800M

Campaign budget for Super PACs and political lobbying

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Realistic All-In Cost per Verified Vote {#sec-treaty_campaign_cost_per_verified_vote_realistic_usd}

**Value**: $1

Realistic all-in cost per verified vote (referral payment + verification cost + overhead)

*Formula*: `REFERRAL_PAYMENT + VERIFICATION_COST + OVERHEAD`

**Methodology**: [../economics/campaign-budget.qmd#verification-cost-analysis](../economics/campaign-budget.qmd#verification-cost-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum Cost per Vote for Mass Mobilization Campaign {#sec-treaty_campaign_cost_per_vote_max_usd}

**Value**: $0

Maximum cost per vote for mass mobilization campaign

**Methodology**: [../strategy/roadmap.qmd#vote-acquisition-cost](../strategy/roadmap.qmd#vote-acquisition-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Minimum Cost per Vote for Mass Mobilization Campaign {#sec-treaty_campaign_cost_per_vote_min_usd}

**Value**: $0

Minimum cost per vote for mass mobilization campaign

**Methodology**: [../strategy/roadmap.qmd#vote-acquisition-cost](../strategy/roadmap.qmd#vote-acquisition-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total 1% Treaty Campaign Cost {#sec-treaty_campaign_total_cost}

**Value**: $1.00B

Total treaty campaign cost (100% VICTORY Social Impact Bonds)

$$
CampaignCost = \$0.3B + \$0.65B + \$0.05B = \$1.0B
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-campaign-vs-implementation](../appendix/fundraising-strategy.qmd#capital-structure-campaign-vs-implementation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Base Case Total Campaign Cost {#sec-treaty_campaign_total_cost_base_case}

**Value**: $840M

Base case total campaign cost (optimistic viral referendum)

$$
CampaignCost_{base} = \$140M + \$650M + \$50M = \$840M
$$

**Methodology**: [../economics/campaign-budget.qmd#base-case-scenario](../economics/campaign-budget.qmd#base-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Realistic Total Campaign Cost {#sec-treaty_campaign_total_cost_realistic}

**Value**: $920M

Realistic total campaign cost (moderate tiered pricing)

$$
CampaignCost_{realistic} = \$220M + \$650M + \$50M = \$920M
$$

**Methodology**: [../economics/campaign-budget.qmd#realistic-scenario](../economics/campaign-budget.qmd#realistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Worst-Case Total Campaign Cost {#sec-treaty_campaign_total_cost_worst_case}

**Value**: $1.11B

Worst-case total campaign cost (high tiered pricing, poor virality)

$$
CampaignCost_{worst} = \$406M + \$650M + \$50M = \$1.106B
$$

**Methodology**: [../economics/campaign-budget.qmd#worst-case-scenario](../economics/campaign-budget.qmd#worst-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Biometric Verification Attempts Multiplier {#sec-treaty_campaign_verification_attempts_multiplier}

**Value**: 1.18

Verification attempts multiplier (1 Ã· conversion rate, assuming 85% completion)

*Formula*: `1 Ã· VERIFICATION_CONVERSION_RATE`

**Methodology**: [../economics/campaign-budget.qmd#verification-cost-analysis](../economics/campaign-budget.qmd#verification-cost-analysis)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Base Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_base_case}

**Value**: $140M

Base case viral referendum budget (assumes flat $0.50/vote, optimistic)

*Formula*: `PLATFORM + VERIFICATION + PAYMENTS_FLAT_RATE`

**Methodology**: [../economics/campaign-budget.qmd#base-case-scenario](../economics/campaign-budget.qmd#base-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Realistic Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_realistic}

**Value**: $220M

Realistic viral referendum budget (moderate tiered pricing)

$$
Budget_{realistic} = \$35M_{platform} + \$59M_{verification} + \$126M_{tiered\ payments} = \$220M
$$

**Methodology**: [../economics/campaign-budget.qmd#realistic-scenario](../economics/campaign-budget.qmd#realistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Worst-Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_worst_case}

**Value**: $406M

Worst-case viral referendum budget (tiered pricing with increasing marginal costs)

$$
Budget_{worst} = \$35M_{platform} + \$59M_{verification} + \$312M_{tiered\ payments} = \$406M
$$

**Methodology**: [../economics/campaign-budget.qmd#worst-case-scenario](../economics/campaign-budget.qmd#worst-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Target Voting Bloc Size for Campaign {#sec-treaty_campaign_voting_bloc_target}

**Value**: 280M

Target voting bloc size for campaign (3.5% of global population - critical mass for social change)

$$
VotingBloc = 8.0B \times 0.035 = 280M
$$

**Methodology**: [../strategy/roadmap.qmd#voting-bloc](../strategy/roadmap.qmd#voting-bloc)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Benefits from All 8 Categories {#sec-treaty_complete_case_annual_benefits}

**Value**: $1.24T

Total annual benefits from all 8 categories (peace dividend + R&D savings + earlier access + research acceleration + rare diseases + drug prices + prevention + mental health)

$$
TotalComplete = \$113.6B + \$50B + \$300B + \$100B + \$400B + \$100B + \$100B + \$75B = \$1,238.6B
$$

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Complete 1% Treaty ROI (All Benefits) {#sec-treaty_complete_roi}

**Value**: 1,239

Complete ROI including all 8 benefit categories (annual benefits Ã· one-time campaign cost)

$$
ROI_{complete} = \frac{\$1{,}238.6\text{B/year}}{\$1.00\text{B}} = 1{,}239:1 \text{ annually}
$$

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lower Bound Conditional ROI {#sec-treaty_complete_roi_conditional_5th_percentile}

**Value**: 44

Lower bound conditional ROI (95% CI lower bound, if treaty passes)

$$
ROI_{conditional,lower} = 44:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Worst-Case Conditional ROI {#sec-treaty_complete_roi_conditional_95th_percentile}

**Value**: 66

Worst-case conditional ROI (95% CI upper bound, if treaty passes)

$$
ROI_{conditional,worst} = 66:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Median Conditional ROI {#sec-treaty_complete_roi_conditional_median}

**Value**: 54

Median conditional ROI (50th percentile, if treaty passes)

$$
ROI_{conditional,median} = 54:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lower Bound Expected ROI {#sec-treaty_complete_roi_expected_5th_percentile}

**Value**: 2.7

Lower bound expected ROI (95% CI, accounting for political risk)

$$
ROI_{expected,lower} = 2.7:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Upper Bound Expected ROI {#sec-treaty_complete_roi_expected_95th_percentile}

**Value**: 27

Upper bound expected ROI (95% CI, accounting for political risk)

$$
ROI_{expected,upper} = 27:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Median Expected ROI {#sec-treaty_complete_roi_expected_median}

**Value**: 14

Median expected ROI (50th percentile, accounting for political risk)

$$
ROI_{expected,median} = 14:1
$$

**Methodology**: [../economics/economics.qmd#probabilistic-analysis](../economics/economics.qmd#probabilistic-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Benefits Using Full Regulatory Delay Avoidance, Consolidating Overlapping Categories {#sec-treaty_comprehensive_with_full_regulatory_delay}

**Value**: $8.54T

Total annual benefits using full regulatory delay avoidance, consolidating overlapping categories

$$
Benefits_{full} = \$1,238.6B - \$300B - \$400B - \$100B + \$11,100B \approx \$11,538.6B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd](../appendix/regulatory-mortality-analysis.qmd)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost per Life for Investor-Funded Scenario (Treaty + dFDA) {#sec-treaty_dfda_cost_per_life_investor_funded}

**Value**: $-7

Cost per life for investor-funded scenario - Treaty + dFDA system

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost per Life Counting Military Spending Opportunity Cost (Treaty + dFDA) {#sec-treaty_dfda_cost_per_life_opportunity_cost}

**Value**: $-5

Cost per life counting military spending opportunity cost - Treaty + dFDA system

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## ICER for Investor-Funded Scenario (Treaty + dFDA) {#sec-treaty_dfda_icer_investor_funded}

**Value**: $-187K

ICER for investor-funded scenario (VICTORY Social Impact Bonds) - Treaty + dFDA system

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## ICER Counting Redirected Military Spending as Opportunity Cost (Treaty + dFDA) {#sec-treaty_dfda_icer_opportunity_cost}

**Value**: $-157K

ICER counting redirected military spending as opportunity cost - Treaty + dFDA system

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Incremental Cost-Effectiveness Ratio per QALY Gained (Treaty + dFDA) {#sec-treaty_dfda_icer_per_qaly}

**Value**: $-2.20K

Incremental Cost-Effectiveness Ratio (ICER) per QALY gained for combined 1% Treaty + dFDA system

*Formula*: `(TREATY_TOTAL_ANNUAL_COSTS - TREATY_TOTAL_ANNUAL_BENEFITS) Ã— 1B Ã· TREATY_TOTAL_QALYS_GAINED_ANNUAL`

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#icer-calculation](../appendix/1-percent-treaty-cost-effectiveness.qmd#icer-calculation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Net Benefit per Life Saved (Treaty + dFDA) {#sec-treaty_dfda_net_benefit_per_life_saved}

**Value**: $-0

Net benefit per life saved for combined 1% Treaty + dFDA system (ICER Ã— QALYs/life)

$$
BenefitPerLife = -\$2{,}197 \times 35 = -\$76{,}895 \text{ per life}
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#cost-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#cost-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Lives Saved from 1% Reduction in Conflict Deaths {#sec-treaty_lives_saved_annual_global}

**Value**: 2,446

Annual lives saved from 1% reduction in conflict deaths

$$
LivesSaved = 244,600 \times 0.01 = 2,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#lives-saved](../appendix/1-percent-treaty-cost-effectiveness.qmd#lives-saved)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Net Annual Benefit from 1% Treaty {#sec-treaty_net_annual_benefit}

**Value**: $163B

Net annual benefit (total benefits - total costs)

$$
NetBenefit = \$163.55B - \$0.29B = \$163.26B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#net-benefit](../appendix/1-percent-treaty-cost-effectiveness.qmd#net-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual QALYs Gained from Peace Dividend {#sec-treaty_qalys_gained_annual_global}

**Value**: 85,610

Annual QALYs gained from peace dividend (lives saved Ã— QALYs/life)

$$
QALYs_{peace} = 2,446 \times 35 = 85,610
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-qalys](../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-qalys)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Benefits from 1% Treaty and dFDA {#sec-treaty_total_annual_benefits}

**Value**: $164B

Total annual benefits (peace dividend + dFDA savings)

$$
TotalBenefits = \$113.55B + \$50B = \$163.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-benefits](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-benefits)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Treaty System Costs {#sec-treaty_total_annual_costs}

**Value**: $290M

Total annual system costs (campaign + dFDA operations)

$$
TotalCosts = \$0.25B + \$0.04B = \$0.29B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-costs](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Benefits from All 8 Benefit Categories {#sec-treaty_total_complete_benefits_annual}

**Value**: $1.24T

Total annual benefits from all 8 benefit categories

$$
TotalBenefits = \$113.55 + \$50 + \$300 + \$100 + \$400 + \$100 + \$100 + \$75 = \$1,238.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#complete-benefits](../appendix/1-percent-treaty-cost-effectiveness.qmd#complete-benefits)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual Lives Saved Equivalent {#sec-treaty_total_lives_saved_annual}

**Value**: 2.12M

Total annual lives saved equivalent (total QALYs Ã· QALYs/life)

$$
Lives_{total} = 74.23M \div 35 = 2.12M
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Daily Lives Saved {#sec-treaty_total_lives_saved_daily}

**Value**: 5,811

Total daily lives saved (dFDA + peace dividend)

$$
Lives_{daily} = 2.12M \div 365 = 5,811
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Annual QALYs Gained {#sec-treaty_total_qalys_gained_annual}

**Value**: 74.2M

Total annual QALYs gained (dFDA + peace dividend)

$$
QALYs_{total} = 74.15M + 85,610 = 74.23M
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-qalys](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-qalys)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## dFDA Trial Completion Speed Multiplier {#sec-trial_completion_speed_multiplier}

**Value**: 10

Trial completion speed multiplier (10x faster)

**Methodology**: [../appendix/research-acceleration-model.qmd#completion-acceleration](../appendix/research-acceleration-model.qmd#completion-acceleration)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Ratio of Type Ii Error Cost to Type I Error Benefit {#sec-type_ii_error_cost_ratio}

**Value**: 1,175

Ratio of Type II error cost to Type I error benefit (harm from delay vs. harm prevented)

$$
\frac{Cost_{delay}}{Benefit_{safety}} = \frac{3.526B}{0.003B} = 1{,}175:1
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#risk-analysis](../appendix/regulatory-mortality-analysis.qmd#risk-analysis)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Maximum DALYs Saved by FDA Preventing Unsafe Drugs {#sec-type_i_error_benefit_dalys}

**Value**: 3

Maximum DALYs saved by FDA preventing unsafe drugs (extreme overestimate)

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#risk-analysis](../appendix/regulatory-mortality-analysis.qmd#risk-analysis)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## US Major Diseases Total Annual Cost {#sec-us_major_diseases_total_annual_cost}

**Value**: $1.25T

Total annual US cost of major diseases (diabetes, Alzheimer's, heart disease, cancer)

$$
Total = \$327B + \$355B + \$363B + \$208B = \$1.253T
$$

**Methodology**: [../solution/aligning-incentives.qmd#insurance-companies](../solution/aligning-incentives.qmd#insurance-companies)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Social Impact Bond Funding in Base Case {#sec-victory_bond_funding_base_case}

**Value**: $498M

VICTORY Social Impact Bond funding in base case (political lobbying, mobilization)

$$
VICTORY_{base} = \$940M \times 53\% = \$498M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Funding as Percentage of Total Campaign Cost {#sec-victory_bond_funding_percentage}

**Value**: 49%

VICTORY bond funding as percentage of total campaign cost (realistic scenario)

$$
VICTORY\% = \frac{\$501M}{\$1,020M} = 49\%
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Social Impact Bond Funding in Realistic Scenario {#sec-victory_bond_funding_realistic}

**Value**: $501M

VICTORY Social Impact Bond funding in realistic scenario (political lobbying, mobilization)

$$
VICTORY_{realistic} = \$1,020M \times 49\% = \$501M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Social Impact Bond Funding in Worst-Case Scenario {#sec-victory_bond_funding_worst_case}

**Value**: $664M

VICTORY Social Impact Bond funding in worst-case scenario (political lobbying, mobilization)

$$
VICTORY_{worst} = \$1,206M \times 55\% = \$664M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Investment Unit for Retail Investors {#sec-victory_bond_investment_unit_usd}

**Value**: $1.00K

VICTORY bond investment unit for retail investors

**Methodology**: [../strategy/roadmap.qmd#victory-bonds](../strategy/roadmap.qmd#victory-bonds)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Annual Payout per $1,000 Victory Bond Investment Unit {#sec-victory_bond_payout_per_unit_usd_annual}

**Value**: $2.72K

Annual payout per $1,000 VICTORY bond investment unit

$$
PayoutPerUnit = \frac{\$2.718B}{\$1B} \times \$1,000 = \$2,718
$$

**Methodology**: [../strategy/roadmap.qmd#victory-bonds](../strategy/roadmap.qmd#victory-bonds)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Legal/Compliance (Realistic) {#sec-victory_legal_compliance_realistic}

**Value**: $47M

VICTORY funding for legal/compliance (political campaign compliance)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Political Lobbying (Realistic) {#sec-victory_lobbying_realistic}

**Value**: $250M

VICTORY funding for political lobbying (US/EU/G20, Super PACs, opposition research)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Operations (Realistic) {#sec-victory_operations_realistic}

**Value**: $30M

VICTORY funding for operations (political campaign staff)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Partnerships (Realistic) {#sec-victory_partnerships_realistic}

**Value**: $71M

VICTORY funding for partnerships (defense industry conversion, political coalitions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Reserve (Realistic) {#sec-victory_reserve_realistic}

**Value**: $13M

VICTORY funding for reserve (political campaign contingency)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Technology R&D (Realistic) {#sec-victory_tech_rd_realistic}

**Value**: $24M

VICTORY funding for technology R&D (political campaign tools)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Funding for Viral Referendum (Realistic) {#sec-victory_viral_referendum_realistic}

**Value**: $143M

VICTORY funding for viral referendum (referral payments, political advertising)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

# Core Definitions {#sec-definitions}

Fundamental parameters and constants used throughout the analysis.

::: {.callout-warning icon=false collapse=false}
## Percentage of Budget Defense Sector Keeps Under 1% Treaty {#sec-defense_sector_retention_pct}

**Value**: 99%

Percentage of budget defense sector keeps under 1% treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## dFDA Patient Eligibility Rate {#sec-dfda_patient_eligibility_rate}

**Value**: 50%

dFDA patient eligibility rate (50% of disease patients can participate)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## dFDA Trial Abandonment Rate {#sec-dfda_trial_abandonment_rate}

**Value**: 5%

dFDA trial abandonment rate (5%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## dFDA Trial Completion Rate {#sec-dfda_trial_completion_rate}

**Value**: 95%

dFDA trial completion rate (95%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## DIH Annual Funding for Medical Research {#sec-dih_treasury_to_medical_research_annual}

**Value**: $24.5B

Annual funding for medical research (treaty funding minus bond payouts)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## DIH Percentage of Treaty Funding Going to Medical Research {#sec-dih_treasury_to_medical_research_annual_pct}

**Value**: 90%

Percentage of treaty funding going to medical research (remainder after bonds)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## GDP Growth Boost 10% {#sec-gdp_growth_boost_10pct}

**Value**: 0.025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## GDP Growth Boost 1% {#sec-gdp_growth_boost_1pct}

**Value**: 0.0025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## GDP Growth Boost 2% {#sec-gdp_growth_boost_2pct}

**Value**: 0.005

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## GDP Growth Boost 5% {#sec-gdp_growth_boost_5pct}

**Value**: 0.0125

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Infections Death Rate {#sec-infections_death_rate}

**Value**: 15

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 10% {#sec-life_extension_years_10pct}

**Value**: 4.12

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 1% {#sec-life_extension_years_1pct}

**Value**: 1.15

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 2% {#sec-life_extension_years_2pct}

**Value**: 1.48

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 5% {#sec-life_extension_years_5pct}

**Value**: 2.47

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 10% {#sec-medical_progress_multiplier_10pct}

**Value**: 412

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 1% {#sec-medical_progress_multiplier_1pct}

**Value**: 115

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 2% {#sec-medical_progress_multiplier_2pct}

**Value**: 148

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 5% {#sec-medical_progress_multiplier_5pct}

**Value**: 247

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Standard Discount Rate for NPV Analysis {#sec-npv_discount_rate_standard}

**Value**: 8%

Standard discount rate for NPV analysis (8% annual)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Standard Time Horizon for NPV Analysis {#sec-npv_time_horizon_years}

**Value**: 10

Standard time horizon for NPV analysis

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 20 1% {#sec-personal_lifetime_benefit_age_20_1pct}

**Value**: 414K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 10% {#sec-personal_lifetime_benefit_age_30_10pct}

**Value**: 3.22M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 1% {#sec-personal_lifetime_benefit_age_30_1pct}

**Value**: 402K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 2% {#sec-personal_lifetime_benefit_age_30_2pct}

**Value**: 592K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 5% {#sec-personal_lifetime_benefit_age_30_5pct}

**Value**: 1.31M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 Half % {#sec-personal_lifetime_benefit_age_30_half_pct}

**Value**: 247K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 40 1% {#sec-personal_lifetime_benefit_age_40_1pct}

**Value**: 369K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 50 1% {#sec-personal_lifetime_benefit_age_50_1pct}

**Value**: 301K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 60 1% {#sec-personal_lifetime_benefit_age_60_1pct}

**Value**: 206K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Conservative Age 30 1% {#sec-personal_lifetime_benefit_conservative_age_30_1pct}

**Value**: 584K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Conservative Moderate Age 30 1% {#sec-personal_lifetime_benefit_conservative_moderate_age_30_1pct}

**Value**: 902K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 10yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_10yr_age_30_1pct}

**Value**: 1.52M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 20yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_20yr_age_30_1pct}

**Value**: 1.96M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 40yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_40yr_age_30_1pct}

**Value**: 2.61M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 5yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_5yr_age_30_1pct}

**Value**: 1.18M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Seconds Per Year {#sec-seconds_per_year}

**Value**: 31.5M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Annual Funding from 1% of Global Military Spending Redirected to DIH {#sec-treaty_annual_funding}

**Value**: $27.2B

Annual funding from 1% of global military spending redirected to DIH

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance {#sec-treaty_campaign_budget_lobbying}

**Value**: $650M

Political lobbying campaign: direct lobbying (US/EU/G20), Super PACs, opposition research, staff, legal/compliance (exceeds pharma $300M + MIC $150M)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Global Referendum Campaign: Ads, Media, Partnerships, Staff, Legal/Compliance {#sec-treaty_campaign_budget_referendum}

**Value**: $300M

Global referendum campaign (get 208M votes): ads, media, partnerships, staff, legal/compliance

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Reserve Fund / Contingency Buffer {#sec-treaty_campaign_budget_reserve}

**Value**: $50M

Reserve fund / contingency buffer

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Treaty Campaign Duration {#sec-treaty_campaign_duration_years}

**Value**: 4

Treaty campaign duration (3-5 year range, using midpoint)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## 1% Reduction in Military Spending/War Costs from Treaty {#sec-treaty_reduction_pct}

**Value**: 1%

1% reduction in military spending/war costs from treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## dFDA Trial Cost Reduction Percentage {#sec-trial_cost_reduction_pct}

**Value**: 50%

Trial cost reduction percentage (50% baseline, conservative)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Annual Victory Bond Payout {#sec-victory_bond_annual_payout}

**Value**: $2.72B

Annual VICTORY bond payout (treaty funding Ã— bond percentage)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Annual Return Percentage for Victory Bondholders {#sec-victory_bond_annual_return_pct}

**Value**: 272%

Annual return percentage for VICTORY bondholders

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Percentage of Captured Dividend Funding Victory Bonds {#sec-victory_bond_funding_pct}

**Value**: 10%

Percentage of captured dividend funding VICTORY bonds (10%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Months to Full Payback for Victory Bondholders {#sec-victory_bond_payback_months}

**Value**: 4.42

Months to full payback for VICTORY bondholders

*Core definition*

:::
